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Abstract 
Obesity has been gradually increasing over the last three decades. The only drugs for the 
long-term obesity treatment currently on the market, approved by both the Food and Drug 
Administration (FDA) and the European Medicines Agency (EMA), are Orlistat, a powerful 
inhibitor of pancreatic lipase derived from a natural compound, Phentermine/Topiramate 
extended release, Exenatide and Dapaglifozin. Recent research has focused on natural 
product discovery for obesity treatment. Compounds isolated from animals, plants, fungi and 
marine phytoplankton have shown promising anti-obesity properties. Cyanobacteria, known as 
blue-green algae and producers of cyanotoxins, have shown high production of secondary 
metabolites with relevant and beneficial activity.  
In this work, we explored the chemical richness of these prokaryotes by testing 
cyanobacterial strains regarding their anti-obesogenic activity in (pre)adipocyte cells, aiming to 
isolate and characterize novel cyanobacterial compounds using a bioassay-guided 
fractionation and isolation approach. Two cell-based screening assays were used, 1) the 
proliferation of pre-adipocytes, and 2) the adipogenesis from pre-adipocytes to mature 
adipocytes. 
The Blue Biotechnology and Ecotoxicology (BBE) group at CIIMAR, offers a unique 
collection of cyanobacteria isolated from water samples and solid materials from the 
Portuguese coast. Six cyanobacterial strains were grown and their extracts were produced. 
These extracts were then fractioned through vacuum liquid chromatography (VLC) and 60 
fractions were obtained. The bioactivity of the resulting fractions was tested in in vitro cultures 
of the murine preadipocyte cell line 3T3-L1 for proliferative and adipogenic activity. Proliferation 
was assessed by the Sulforhodamine B (SRB) staining and the incorporation of 
Bromodeoxyuridine (BrdU) into the DNA.  Furthermore, the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay (MTT bioassay) delivers information about the cellular 
viability and metabolic activity, through the reduction of MTT to formazan. Effects on 
adipogenesis were assessed using imaging techniques and Oil Red O lipid staining. 
The strongest effects on proliferation rate were obtained after the exposure to fractions of 
Planktothrix planctonica LEGEXX280 (E14028 I) and Aphanizomenon sp. LEGE03283 
(E14035 B); the strongest effects on adipogenesis were obtained from fractions of 
Synechocystis sp. LEGE07211 (E14031 D) and Oscillatoria limnetica LEGE00237 (E14032 H). 
The most promising fractions were selected for further sub-fractionation using wet chemistry 
extraction techniques as solid phase extraction (SPE) and high pressure liquid chromatography 
(HPLC). Sub-fraction E14028 I7 8A+9 E7 J1 is the result of seven fractionations, showing 
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promising pro-proliferative and metabolic activity. The compound is now isolated with few 
impurities. Sub--fraction E14031 D7 exerted strong pro-adipogenic effects and a further sub-
fractionation is being processed. Compound isolation will take place in the following steps. 
The combined in vitro 3T3-L1 screening with the production of cyanobacterial compounds 
allows us advance in the isolation of natural compounds with pro-proliferative and pro-
adipogenic activities that in the future may be beneficial for the treatment of obesity-related co-
morbidities.  
Furthermore, during this work, a review was submitted to Current Topics in Medicinal 
Chemistry (Appendix II) with the title “Obesity: the metabolic disease, advances on drug 
discovery and natural product research”, which gives a summary of the state of the art of natural 
compound discovery related to obesity treatment. 
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Resumo 
 A obesidade tem vindo a aumentar gradualmente ao longo das últimas três décadas. 
Os únicos fármacos actualmente no mercado para o tratamento da obesidade a longo prazo, 
aprovados pela Food and Drug Administration (FDA) e a Agência Europeia de Medicamentos 
(EMA) são Orlistat, um potente inibidor das lipase pancreatica derivado de um composto 
natural, a Associação Fentermina / Topiramato, Exenatida e Dapaglifozina. A pesquisa mais 
recente foca-se na descoberta de produtos de origem natural para o tratamento da obesidade. 
Compostos isolados a partir de animais, plantas, fungos e algas marinhas têm mostrado 
promissoras actividade anti-obesidade. Cianobactérias, conhecidas como algas verde-
azuladas e produtoras de toxinas, têm demonstrado elevada produção de metabolitos 
secundários de alto valor biotecnológico, farmaceutico e industrial.  
Neste trabalho exploramos a riqueza química destes procariontes, testando frações de 
determinadas estirpes de cianobactérias por actividade anti-obesogénica em pré-adipócitos.O 
objectivo é isolar e caracterizar novos compostos de cianobactérias, utilizando um sistema de 
fraccionamento guiado por bioactividade. Foram utilizados dois ensaios celulares para 
determinação de bioactividade: 1) a proliferação de pré-adipócitos, e 2) a adipogénese de pre-
adipócitos em adipócitos maduros. 
O grupo Blue Biotechnology and Ecotoxicology (BBE) no CIIMAR oferece uma coleção 
única de cianobactérias isoladas de amostras de água e materiais sólidos da costa 
Portuguesa. Várias estirpes de cianobactérias foram cultivadas e os seus extratos foram 
produzidos.Estes extractos foram então fracionados utilizando cromatografia líquida sob-
vácuo de fase normal. A bioactividade das frações preparadas foi testada em cultura in vitro 
da linha de pré-adipócitos 3T3-L1 por actividade pro-proliferativa e pro-adipogénica. A 
proliferação foi avaliada com o uso da coloração por Sulforrodamina B (SRB) e a incorporação 
de Bromodeoxiuridina (BrdU) no ADN. Além disso, o bioensaio da redução do brometo 3-(4.5-
dimetiltiaziol-2-il)-2.5-difeniltetrazolio (MTT) forneceu informação sobre a viabilidade celular e 
actividade metabólica. A adipogénese foi avaliada usando o Oil Red O. 
De seis estirpes cianobacterianas, 60 fracções foram obtidas. Os efeitos mais fortes na 
actividade proliferativa foram obtidos após a exposição a uma fração de  Planktothrix 
planctonica LEGE XX280 (E14028 I) e a uma fração de Aphanizomenon sp. LEGE03283 
(E14035 B); enquanto que os efeitos mais fortes na adipogénese foram obtidos na exposição 
às fracções das estirpes Synechocystis sp. LEGE07211 (E14031 D) e Oscillatoria limnetica 
LEGE00237 (E14032 H). 
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As frações mais promissoras foram selecionadas para posterior sub-fraccionamento. A 
sub-fração E14028 I7 8A+9 E7 J1 é o resultado de sete fracionamentos, com actividade 
proliferativa e metabólica promissora. Este composto encontra-se agora isolado com algumas 
impurezas.A sub-fracção E14031 D7 exerceu também fortes efeitos adipogénicos e está a ser 
processada.  
Os testes in vitro utilizando a linha celular 3T3-L1 permitem a triagem de vários compostos 
de cianobactérias, para além de permitirem testar variados parâmetros essenciais para o 
estudo da obesidade. 
Durante este trabalho, uma revisão foi submetida à revista Current Topics in Medicinal 
Chemistry (Apêndice II) entitulada “Obesity: the metabolic disease, advances on drug 
discovery and natural product research”, uma revisão que sumariza o estado da arte da 
descoberta de compostos naturais de interesse ao tratamento da obesidade. 
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1. Introduction 
Obesity is a global hazard associated with health problems such as hypertension, high 
cholesterol, diabetes, cardiovascular diseases, respiratory problems (asthma), 
musculoskeletal diseases (arthritis) and some forms of cancer (Fox et al. 2007). In the last 20 
years, the percentage of obesity has nearly doubled in many European countries. The highest 
rates of obese adults are found in Mexico, followed by New Zealand and the United States, 
representing more than one third of the population, whereas in Asian countries the rates are 
between 2 and 4% (OECD, 2014). The promotion of a healthy lifestyle and lifestyle changes 
are preventive and straightforward. However, a large percentage of the world’s population may 
not be able to depend on this methodology alone, when treating obesity. Throughout history, 
pharmaceutical companies have been unable to develop safe and effective anti-obesity drugs. 
Despite the increasing need, the only drugs for the long-term obesity treatment currently on the 
market, approved by both the Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA), are Orlistat, a powerful inhibitor of pancreatic and intestinal lipases 
derived from a natural compound, Phentermine/Topiramate extended release, Exenatide and 
Dapaglifozin. A demand is present for new anti-obesogenic drugs without major toxicological 
side-effects.  
Natural products are recognized as an extremely rich source of new beneficial compounds 
with high impact on drug development for infectious, neurological, cardiovascular, 
immunological, inflammatory and oncological human diseases (Butler et al. 2014). Natural 
products are produced by a wide array of living organisms as vertebrate and invertebrate 
animals, plants, marine phytoplankton, fungi and bacteria. The marine and freshwater 
environment, recognized as the richest ecosystems, are currently the main sources of natural 
compounds, wherein cyanobacteria represent a promising and fruitful source (Nagarajan et al. 
2012). Cyanobacteria are being studied in high-scale due to their capability of producing many 
secondary metabolites with unusual structures and powerful activities against cancer and other 
diseases; cyanobacteria are thus an exciting source for leads in drug discovery. 
1.1. Obesity 
1.1.1. Dynamics of the Adipose Tissue 
The perception of the adipose tissue changed markedly from simple fat storing cells to 
hormone-secreting cells with impact on the whole-body metabolism, energy metabolism in 
distant tissues, and sensitivity regulation towards insulin signaling. Today, adipocytes are 
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recognized as critical regulators of the whole-body metabolism (Stephens 2012).  The tissue is 
composed of many cell types, as endothelial cells, hematocytes, pericytes, preadipocytes, 
macrophages and other immune cells (Geloen et al. 1989). However, in mammals, the adipose 
tissue is mainly constituted by two morphologically and physiologically very different types of 
cells: white adipocytes are cells with a single cytoplasmic lipid droplet and a squeezed nucleus, 
whereas brown adipocytes are polygonal cells with a round nucleus, several cytoplasmic lipid 
droplets and numerous large mitochondria. These two types of cells also differ in their 
distribution in the human body: white adipocytes are mostly found in subcutaneous (under the 
skin) and visceral depots (near internal organs), while brown adipocytes are found in visceral 
depots and near the aorta (Barbatelli et al. 2010). Brown adipose tissue (BAT) is exclusive to 
mammals and recognized as an evolutionary advantage, since it is specialized in body 
temperature maintenance, allowing mammals to survive during cold stress. This function is 
mediated by uncoupling protein-1 (UCP1) in the mitochondria (Farmer 2008), an exclusive 
protein of the BAT. Scientists also consider a third type of adipose tissue which is under intense 
investigation, but its origin and function remain unclear. Beige adipocytes (Ishibashi & Seale 
2010) are regions in the white adipose tissue containing brown or brown-like adipocytes. Since 
the adipose tissue responds to physiological and environmental stimuli, due to its high density 
in nerve fibers in contact with adipocytes (Bartness et al. 2010), beige adipocytes were seen 
to arise after environmental and hormonal stimuli. Beige adipocytes within the white adipose 
tissue were found to be originated from white adipocytes with the expression of positive 
regulatory domain containing 16 (PRDM16), a transcriptional modulator required for 
thermogenesis (Ishibashi & Seale 2010), when under β3-adrenergic stimulation, chronic 
activation of peroxisome proliferator-activated receptor gamma (PPAR-γ) or adaptation to cold 
response (Petrovic et al. 2010); this process is also known as white-to-brown 
transdifferentiation (Himms-Hagen et al. 2000).  
Adipocytes have also been known to play a role in endocrine functions, and secrete 
important hormones and peptides for energy homeostasis, vascular diseases and appetite 
regulation. Hormones produced specifically from adipocytes are considered to be important 
regulators of whole-body metabolism. Leptin was the first characterized hormone to be 
secreted by the adipose tissue (Zhang et al. 1994). Leptin is responsible for appetite and food 
uptake, directed by anorexigenic (appetite suppressing) or orexigenic (appetite stimulating) 
neuropeptides. When the adipose tissue decreases in mass, leptin levels decline and 
neuropeptide Y levels rise, leading to higher food intake. Weight gain increases the adipokine 
levels, resulting in decreased food intake.  Through this feedback mechanism, leptin is able to 
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regulate body fat mass and adipose tissue mass. Pivotal roles of this hormone have been 
described as regulation of the reproductive, cognitive, immune system, and related 
autoimmune disorders, as well as bone metabolism and hematopoiesis.  Other hormones 
produced by adipocytes are for example adiponectin or resistin. Adiponectin acts on the 
regulation of many physiological processes as glucose and lipid metabolism (Kadowaki & 
Yamauchi 2005). Resistin, mainly produced by monocytes and macrophages within the 
adipose tissue, is involved in the pathogenesis of insulin resistance (McTernan et al. 2006). 
The adipose tissue is crucial for a well-functioning metabolism and characterized as a complex 
organ due to its inherent plasticity, its ability to increase or decrease the number of constituent 
cells, and its transdifferentiation potential. 
1.1.2. The Metabolic Disease 
Obesity is a complex metabolic disorder, characterized by the accumulation of fat in 
different body regions, which is caused by a positive energy balance. Obesity, at the cellular 
level, is manifested as the increase in cell size (hypertrophy) and cell number (hyperplasia) and 
both of these processes are largely dependent on the regulation of adipocyte differentiation 
(Rosen & MacDougald 2006). Metabolic complications of obesity are type 2 diabetes mellitus 
(T2DM), non-alchoholic fatty liver disease, cardiovascular disease or cancer.    
Interaction between genetic, behavioral and environmental factors has been proven to lead 
to obesity. Excessive nutrient intake, lack of exercise and genetic susceptibility are established 
as the main causes of obesity (Ogden et al. 2012). However, well-known endocrine disrupting 
chemicals, such as phthalates, bisphenol A and alkylphenols,  interfere with the individual 
hormonal levels, hence leading to high prevalence of obesity or developing obesity (vom Saal 
et al. 2012; Tang-Péronard et al. 2011).  Interestingly, associations exist between gut 
microbiota composition and obesity. The mechanisms through which these microbes exert their 
anti-obesity effects are still unclear. However, links have been made between two distinct 
phylums of bacteria: the phylum Firmicutes is associated with obesity, whereas the phylum 
Bacteroidetes is associated with weight loss. Furthermore, the transplant of microbiota from 
obese or western diet-fed mice to lean mice resulted in weight gain (Ley et al. 2006).  
Adipocyte plasticity is critical for insulin sensitivity and overall metabolic health. 
Consequently, disturbances of adipocyte regulation are the origin of some metabolic diseases 
such as T2DM. However, T2DM and obesity are not exclusively correlated. Some obese people 
are diabetic but a huge percentage of the population is non-diabetic obese people, identified 
as metabolically healthy obese (Blüher 2014). Metabolically healthy obese people have well-
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functioning adipocytes and thus a lower mortality risk. The correlation commonly seen between 
obesity and T2DM is insulin resistance, characterized by cells becoming resistant to the effects 
of insulin and therefore glucose uptake.  Physiological transformations in the adipose tissue, in 
particular adipocyte hypertrophy, adipocyte death and adipocyte stress result in increasing 
adipocyte remnants that need absorption by specialized cells as macrophages. Chronic 
deposition of these remnants causes therefore the chronic deposition of macrophages in the 
adipose tissue, which finally causes inflammation (Yao et al. 2014). The higher presence of 
macrophages lead to higher content in cytokines in the obese adipose tissue; furthermore, 
circulation of free fatty acids (FFAs) and FFAs depots in non-adipose tissues, as muscles, can 
also contribute to insulin resistance through the release of chemoattractant proteins (Guilherme 
et al. 2008). Cytokines as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1α 
(IL-1α) and interferon gamma (IFNγ) inhibit cellular proliferation and differentiation and lead to 
insulin resistant-mature adipocytes (Finucane et al. 2012). Cytokines, and in particular TNFα, 
are potent inhibitors of adipocyte differentiation via the PPARy receptor, and lead to decreased 
triglyceride deposition and higher serum fatty acid levels. Resulting consequences are ectopic 
lipid deposition and impaired glucose transport, which ultimately cause insulin resistance in 
mature adipocytes or muscle cells. Significantly reduced insulin receptor substrate 1 (IRS-1) 
and protein kinase B (PKB) phosphorylation levels were observed in adipocytes from patients 
with T2DM. Concomitantly, high levels of pro-inflammatory cytokines (IL-6 and nuclear factor 
kappa-light-chain-enhancer (NF-κB) of activated B cells) were detected (Wang et al. 2011). 
Nitric oxide released by macrophages may as well be responsible for increasing the 
susceptibility of adipocytes to become resistant to insulin (Kraus et al. 2012).  
The metabolic complications of obesity may also be a result of other stimuli, which are 
present in the expanding adipose tissue microenvironment. Hypoxia, due to the rapid tissue 
expansion, results in higher levels of fatty acids and products of cell death, and causes 
migration of innate and adaptive immunity system cells, which in turn lead to inflammation of 
the adipose tissue (Surmi & Hasty 2008). Hence, inflammatory conditions due to adipose tissue 
expansion is another underlying cause of T2DM development (Phieler et al. 2013; 
Chatzigeorgiou et al. 2014).  
Obesity has further been linked with a series of cancers. Hormone dependent cancers as 
postmenopausal breast and ovarian cancers can be of higher incidence in individuals with high 
body mass and fat index, since adipokines as leptin are increased in obesity and have pro-
inflammatory activities.  Leptin exerts its activity through leptin receptor and Fusco et al. (2010) 
showed that inactivation of this receptor inhibits proliferation and viability of human breast 
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cancer cell lines. The association between obesity and cancer was also demonstrated in vitro 
by the fact that glucose and fatty acids modulated the growth factor and cytokine secretion of 
adipocytes, which in turn induced the proliferation of cancer cells (D’Esposito et al. 2012). 
Even though there is little information about behavioral and obesity profiles, certain 
neurotransmitters are linked with this disease. Neurotransmitters as dopamine and 
norepinephrine have been found to modulate the food intake. The relationship between the 
stimuli to higher or lowered food intake is thought to be the underlying mechanism. Dopamine 
has been described to modulate food reward through the meso-limbic circuitry of the brain 
(Martel & Fantino 1996). Blockers of dopamine D2 receptors result in increases of appetite and 
weight gain (Baptista 1999); while drugs that increase brain dopamine concentration present 
anorexigenic (appetite suppressing) properties (Towell et al. 1988; Foltin et al. 1990). Food 
intake can be mediated as well by the endogenous levels of norepinephrine.  Decreases in 
norepinephrine  will lead to lowered food intake, (Bays & Dujovne 2002) and serotonin and 
norepinephrine reuptake inhibitors induce satiety and effectively reduce the accumulation of 
abdominal fat (Hainer et al. 2006). The availability of norepinephrine transporter is decreased 
in the thalamus of obese individuals, supporting a link between noradrenergic dysfunction and 
norepinephrine levels in obesity (Li et al. 2014).  
Moreover, physical activity is also an important regulator of obesity via alteration of 
neurotransmitter level or inflammatory cytokines. Decreases in bodily activity (e.g. sedentary 
lifestyle) can lead to lowered noradrenergic levels, causing weight gain. Cardiorespiratory 
fitness was demonstrated to help preventing by decreasing inflammation and by protecting 
against adrenergic desensitization. Inflammatory cytokines were described to desensitize β -
adrenergic receptors to their ligands by elevating G protein–coupled receptor kinase-2 (GRK-
2) (Eisenhut 2012). Several studies that reported weight loss, either through hypocaloric diet, 
exercise or liposuction, observed the reduction of the levels of circulating cytokines, as IL-6 and 
TNF-α, due to the  decrease in adipose tissue mass (Polak et al. 2006; Esposito et al. 2002). 
Also, neurohormones as catecholamines, adenosine and dopamine, which are higher during 
exercise, have the ability to inhibit pro-inflammatory functions of macrophages (Bush et al. 
1999; Van Der Horst et al. 1999). 
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1.1.3. Model systems for obesity studies 
Model cell culture systems have been vital in obesity studies. Preadipocyte cell lines, as 
3T3-F442A and 3T3-L1, were first established as a valid model system in the laboratory of 
Green (Green & Meuth 1974). Both were originally developed by clonal expansion from murine 
Swiss 3T3 embryo cells and became a standard for studying preadipocyte differentiation, due 
to its efficiency to differentiate from fibroblasts to adipocytes.  
1.1.3.1. Pre-adipocyte Proliferation 
 
Preadipocyte differentiation and proliferation are the main factors determining the mass of 
the white adipose tissue. The adipose tissue derives from pluripotent mesenchymal stem cells. 
These cells have the ability to undergo differentiation into adipocytes, myocytes, chondrocytes 
and osteocytes (Pereira-Fernandes et al. 2014) depending on the stimuli received. 
Differentiation into adipocytes requires passage through a preadipocyte stage, which, under 
appropriate conditions, will originate mature adipocytes. Pre-adipocyte proliferation occurs 
through clonal expansion and represents the initial steps towards adipogenesis, determining 
the number of mature adipocytes throughout adulthood. During proliferation, some genes are 
significantly up-regulated as cyclin B2, cyclin D1 and cyclin E1, proliferating cell nuclear antigen 
(PCNA) and the insulin-like growth factor-1 (IGF-1) that is a potent activator of the protein 
kinase B (Akt) pathway leading to cell growth and proliferation. 
 
1.1.3.2. Pre-adipocyte Differentiation 
During adipogenesis, pre-adipocytes lose their fibroblastic morphology, start to accumulate 
triglycerides into their characteristic fat droplets, and acquire the appearance and metabolic 
features of mature adipocytes (Green & Meuth 1974). To trigger the cascade of cell 
differentiation, protocols have been developed for effective differentiation. At the point of growth 
arrest, cells can be exposed to a differentiation cocktail composed of agents such as insulin or 
adrenergic agents (epinephrine, cellular cyclic adenosine monophosphate (cAMP)). For the 
complete differentiation of the cell line 3T3-L1, an appropriate and effective cocktail has been 
established containing insulin, dexamethasone (DEX), and 3-isobutyl-1-methylxanthine (IBMX) 
(Mendes et al. 2008). Insulin acts through the activation of the IGF-R signaling pathway, altering 
the expression of the sterol regulatory element-binding protein-1 (SREBP-1), resulting in the 
stimulation of glucose transporter type 4 (GLUT4) - mediated glucose uptake and lipid 
synthesis; dexamethasone acts through the glucocorticoid signaling pathway, with an opposite 
action as of cortisol, ultimately activating the CCAAT-enhancer-binding proteins β and γ 
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(C/EBPs) and inhibiting fat breakdown; IBMX is an agent used to elevate cAMP, leading to 
phosphorylation of the cAMP response element-binding protein (CREB) that activates the 
expression of endogenous C/EBP-α, a transcription factor crucial for adipocyte differentiation 
and lipid synthesis and accumulation. PPAR-γ is a nuclear receptor with an active role in the 
regulation of adipogenesis, stimulating the expression of target genes involved in adipocyte 
differentiation and increased lipid storage (Sarjeant & Stephens 2012) (Figure 1). 
 
Figure 1 – Factors intervening in 3T3-L1 preadipocyte differentiation. (Insulin (INS), 3-isobutyl-1-methylxanthine 
(IBMX), dexamethasone (DEX), cyclic adenosine monophosphate (cAMP), cAMP-responsive element binding 
protein (CREB), sterol regulatory element-binding protein-1 (SREBP-1), CCAAT-enhancer-binding proteins 
(C/EBPs) and peroxisome proliferator-activated receptor-γ (PPAR-γ)). 
1.2. Natural Compound Discovery 
Drug discovery is an active research area, with a broad selection of drug candidates and 
increasing investment. Natural compounds from organisms as primary metabolites (steroids, 
nucleosides, etc.), vitamins, hormones, protein fragments, herbal mixtures and polyamines fall 
into the category of natural product drugs, even if they are synthetically produced, whereas 
compounds inspired from a natural product template, but synthetically derived are considered 
natural product derived drugs. Semi-synthetic drugs of natural origin had a natural compound 
as a template, and currently marketed with some modifications and synthetically produced. 
Synthetic drugs don’t share similarities with known natural compounds and are therefore 
synthetically derived.  In the pipeline of drug discovery are now thousands of drug-like 
chemicals in the various phases of clinical trials. In 2010, around 10% of the drugs on the 
market were unaltered natural products, 29% derived from natural products, known as semi-
synthetic, and the rest (61%) was composed with compounds of synthetic origin (Bate et al., 
2010). Between 2000 and 2013, 25% (14 out of the 56) approved drugs with natural origin were 
unaltered natural products, while the majority were semi-synthetic natural products (Butler, et 
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al. 2014). These numbers underline the importance of natural product discovery. Important 
therapeutic areas for new natural products and semi-synthetic natural compounds are oncology 
and infectious diseases, which make up to 64% of the natural drug targets (Butler et al. 2014). 
The first two marine-derived natural products used to treat human disease were 
Cytarabine (Cytosar-U®, Depocyt®), a synthetic pyrimidine nucleoside last approved by the 
EMA in 2001 for the treatment of cancer, and Vidarabine, a synthetic purine nucleoside with 
antiviral properties, both developed from natural compounds from the Caribbean sponge 
Tethya crypta (Newman et al. 2009). About 6 years later, Ziconotide (Prialt®), was approved 
for the treatment of moderate to severe pain. Ziconotide is the synthetic formula of a 25-amino 
acid peptide, originally isolated from the venom of the marine snail Conus magus (Olivera 
2000). Trabectedin (Yondelis®) is another marine-derived product with EMA’s approval in 2003  
for the treatment of soft tissue sarcoma and ovarian carcinoma, isolated from the tunicate 
Ecteinascidia turbinate found in the Caribbean and Mediterranean seas (Wright et al. 1990). In 
2010, the FDA and EMA approved Halichindrin B, a polyether isolated from the marine sponge 
Halichondria okadaic, for the treatment of metastatic breast cancer: (Hirata & Uemura, 1986).  
Brentuximab vedotin (Adcetris™) was approved by the FDA in 2011 for patients with 
classical Hodgkin’s lymphoma, peripheral T-cell lymphoma, diffuse large B-cell lymphoma or 
systemic anaplastic large cell lymphoma (Stathis & Younes 2015). This compound is a novel 
anti-body drug conjugate composed by a chimeric monoclonal anti-CD30 antibody, cAC10, 
directing this compound specifically into CD30-positive malignancies, and a cathepsin-
cleavable linker as a backbone to carry monomethyl auristatin E (MMAE) (Ansell 2014). MMAE 
is a synthetic compound derived from dolastatin 10 that was first isolated from the sea hare 
Dolabella auricularia with potent antineoplastic activity (Pettit et al. 1987). The compound was 
later found to be produced by the cyanobacteria Symploca hydnoides and Lyngbya majuscula, 
which are part of the sea hare’s diet (Niedermeyer & Brönstrup 2012). 
1.2.1. Anti-obesity Natural Compounds 
The potential of natural compounds on drug development has been widely explored and 
proven to be a reliable and fruitful source. Therefore, isolation and characterization of novel 
functional compounds from biological organisms has gained much attention. 
Many natural compounds have been studied that demonstrated interesting activities for the 
prevention and treatment of obesity and related metabolic complications as diabetes and 
cardiovascular disease. Most of the research employed in vitro methodologies (e.g. modulation 
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of the differentiation of 3T3-L1 cell line), in vivo techniques (e.g. adipose mass tissue decreases 
in mice or rats), or direct enzymatic assays (e.g. lipase activity screening). 
As of December 2013, four drugs have been approved by both the FDA and the EMA for 
chronic weight management and obesity complications: Orlistat (Alli®, GlaxoSmithKline; 
Xenical®, Roche), Phentermine/topiramate extended release (Qsymia®, Vivus), Exenatide 
(Byetta®, Bydureon®) and Dapaglifozin (Forxiga®). The FDA has also approved Lorcaserin 
(Belviq®, Arena Pharmaceuticals), Pramlintide (Symlin®,Amylin Pharmaceuticals ) and 
Phentermine (Qnexa®, Vivus), for the long-term treatment of obesity in 2012. Phentermine and 
Lorcaserin are two appetite suppressants used for the treatment of obesity through 
noradrenergic activation. Pramlintide is the synthetic analogue of amylin that promotes satiety 
and inhibits the secretion of glucagon. However, EMA has rejected these drugs due to limited 
efficacy, carcinogenic and teratogenic potential, cardiovascular events and cognitive 
impairment, considering that their side-effects would not outweigh their benefits. Many natural 
compounds have been studied and shown interesting activities for the prevention and treatment 
of diabetes, obesity and cardiovascular diseases. The drugs usually applied in obesity 
treatment can be mainly divided in four groups: drugs suppressing appetite, drugs increasing 
insulin sensitivity, drugs targeting sodium/glucose co-transporters and drugs decreasing lipid 
absorption.  Natural compound discovery on obesity treatment has, however, focused mainly 
on compounds that act on lipid absorption and insulin resistance.  
Most of the research focused on in vitro, using appropriate cell lines, and in vivo techniques, 
using model systems as mice or rats, while others focused on direct enzymatic assays for lipase 
activity screening. Some of the latest articles describing anti-obesity natural products have 
shown promising activities, through direct pancreatic lipase inhibition as for the methyl 
xestospongic ester from the marine sponge Xestospongia testudinaria (Liang et al. 2014), the 
methanol extract of the brown algae Eisenia bicyclis, composed mainly of phlorotannins (Eom 
et al. 2013), flower buds of Splilanthes acmella (Ekanem et al. 2007),   and galangin, a flavonol 
glycoside isolated from Alpinia galanga Wild, a plant from the ginger family (Kumar & Alagawadi 
2013).  
The identified compounds found to have anti-obesity properties also have various and 
numerous chemical identities. Many phenols had a direct activity on 3T3-L1 pre-adipocyte 
differentiation. Phenols are naturally present in a wide variety of organisms. Cathechins from 
green tea leaves (Ahmad et al. 2015), licochalcone A from the root of Glycyrrhiza glabra (Quan 
et al. 2012), tyrosol from Rhodiola crenulata (Lee et al. 2011) and dehydrodiconiferyl alcohol 
from Cucurbita moschata (Lee et al. 2012) are phenols and polyphenols with described anti-
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obesity activities. Terpenes are also a representative group of identified natural compounds, 
with either neurohormonal activity, as the xylarenals A and B from Xylaria persicaria (Smith et 
al. 2002), or adipose tissue mass regulation properties, as for the ursolic acid from Sambucus 
australis Cham. (Rao et al. 2011). Polysaccharides from marine brown algae also showed 
interesting activity, namely the main active compounds L-fucose (sugar) and sulphate ester 
groups that stimulated lipolysis through hormone sensitive lipase activation (Kim et al. 2009). 
Two polyketides, moccasin and ankaflavin from the mold Monascus sp., also inhibited adipose 
tissue differentiation and lipogenesis in vitro (Jou et al. 2010). 
Natural compounds acting on the regulation of neurohormone levels and UCP modulation, 
an important protein involved in thermogenesis and a possible therapeutic target for obesity, 
have been described as well. Xylarenals A and B, two sesquiterpenoids, isolated from the 
ascomycete Xylaria persicaria, were found to be selective antagonists for the Neuropeptide Y5 
(Smith et al. 2002), which is a receptor found in peripheral and central nervous system, involved 
in mediating food intake and body weight (Schaffhauser et al. 1997). Fucoxanthin, a carotenoid 
from Undaria pinnatifida (Miyashita et al. 2011) and evodiamine, an alkaloid traditionally used 
in China as a “fat burner” (Kobayashi et al. 2001) induced UCP-1 expression; phytochemicals 
from the leaves of Peucedanum japonicum Thunb increased the expression of the UCP-3 gene 
in muscle (Nukitrangsan et al. 2012).   
A new group of compounds currently being studied are the sodium/glucose co-transporter 
(SGLT) inhibitors, derived from the natural product phlorizin, a polyphenol.  Phlorizin blocks the 
absorption of glucose in the SGLT-2 present in the nephrons, resulting in decreases of glucose 
reabsorption. This represents a novel therapeutic approach to diabetes that is independent of 
insulin secretion or action. Preclinical and clinical studies of SGLT2 inhibitors in subjects with 
T2DM, as well as genetic mutations in kidney-specific SGLT2 that result in no adverse 
sequelae, appear to support this strategy (Ehrenkranz et al. 2005). Synthetic compounds 
derived from phlorizin were actually seen to be more effective and selective, mainly due to the 
reduced degradation by glucosidase enzymes and increased intestinal absorption (Ehrenkranz 
et al. 2005). Many natural product derived drugs acting on SGLT have been developed. 
Dapagliflozin (Farxiga®, Forxiga®) and canagliflozin (Invokana®) were approved by the EMA 
and many other analogues are currently in phase III and phase II clinical trials. 
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1.2.2. Cyanobacteria as a source of natural compounds 
 
1.2.2.1. Cyanobacteria 
 
Phytoplankton has been found in almost every ecological niche of aquatic systems, 
recognized for its crucial contribution to ecosystems in atmospheric oxygen renewal and sink 
for carbon dioxide. Even though they represent less than 1% of Earth’s biomass, phytoplankton 
organisms are primary producers, highly important to every food chain.  
Cyanobacteria have fossil records from over 2 billion years ago and are widely distributed 
through terrestrial, marine and freshwater ecosystems. They are the only bacteria capable of 
oxygenic photosynthesis and their high adaptability to each ecosystem could be the reason 
why they are so prolific in secondary metabolites. The need for UV protection, feeding 
avoidance (Cruz-Rivera & Paul 2007) or for microbial communication as quorum sensors 
(Sharif et al. 2008) led them to produce ecologically significant compounds. Cyanobacteria are 
gram-negative photosynthetic prokaryotes, believed to be at the origin of the rise of 
atmospheric oxygen, an event known as the Great Oxidation Event. Cyanobacteria lack 
flagella, however, they are able to move in the water column using atmospheric nitrogen as a 
buoyancy regulation mechanism. Other environmental adaptations include the ability to 
reproduce through differentiated cells (hormogonia) and to, when in stress (periods of lowered 
light, nutrients or water) thrive through resting cells, known as akinets, a survival cell used for 
storing nutrients, or heterocysts, used for nitrogen fixation when nitrogen sources are depleted 
(Madigan et al. 2010). 
Cyanobacteria are a Phylum that belongs to the Bacteria Domain. Morphologically, they 
are 2 to 40 µm diameter organisms with a complex cell wall constituted by a thick peptidoglycan 
layer and periplasmic space between the inner cytoplasmic membrane and the outer cell 
membrane. The outer cell membrane is composed by lipopolysaccharides, phospholipids and 
proteins, while the intracellular space is composed of proteins, enzymes and metabolites 
(Madigan et al. 2010). 
Cyanobacteria taxa was determined according to the Botanical Code of Nomenclature and 
includes five major groups as was proposed by Rippka et al. (1979): I (Chroococcales) — 
unicellular cyanobacteria that reproduce by binary fission or budding, II (Pleurocapsales) —
unicellular cyanobacteria that reproduce by multiple fission, III (Oscillatoriales) — filamentous 
non-heterocystous cyanobacteria that divide in only one plane, IV (Nostocales) — filamentous 
heterocystous cyanobacteria that divide in only one plane, V (Stigonematales) —filamentous 
heterocystous cyanobacteria that divide in more than one plane (Boone & Castenholz 2001). 
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1.2.2.2. Bioactive compounds from Cyanobacteria 
Cyanobacteria can have negative impacts on ecosystems. They are known to produce 
toxins, causing the death of animals and harmful algal blooms in eutrophicated aquatic 
systems, detrimental to water quality and biological variability.  However, recent research 
enlightened the ability of cyanobacteria to synthesize other compounds highly relevant for 
economical, industrial, medicinal and biological fields. 24% of the commercially available 
natural products for biomedical research are of cyanobacterial origin (Gerwick & Moore 2012).   
 
 
 
 
 
 
 
 
 
 
 
Figure 2 – Pie chart for the distribution of reported cyanobacterial secondary metabolites through the five major 
botanical sub-classes (adapted from Gerwick et al. 2008). 
Compounds from cyanobacteria have been seen to interact with specific cellular targets 
such as actin filaments, microtubules and proteasome, explaining why they are so prolific in 
compounds for disease treatment. The main focus has, however, been in drug discovery for 
cancer treatment and some of the described molecules have been in preclinical and/or clinical 
trials as potential anticancer drugs (Gerwick et al., 2001).  
Up to now, more than 800 metabolites have been described from various taxa and beyond 
that, one single strain of cyanobacteria is able to produce a wide array of structurally different 
secondary metabolites. Filamentous marine cyanobacteria from subclass III (Oscillatoriales) 
represent nearly half of the 800 compounds reported so far (Gerwick et al. 2008). From a single 
I I I  (Oscillatoriales)
49%
IV (Nostocales)
26%
I  (Chroococcales)
15%
II (Pleurocapsales)
6%
V (Stigonematales)
4%
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genus, there are almost 300 compounds described, 236 compounds are ascribed to Lyngbya 
majuscula and a further 11 to L. bouillonii (Gerwick et al. 2008). 
Certain genera of marine cyanobacteria as Lyngbya, Oscillatoria, Nostocales, Symploca, 
Calothrix, Leptolyngbya, Dichothrix, among others, have been shown to produce many 
secondary metabolites with several chemical identities. Even though the majority of studies 
report beneficial biological compounds from filamentous and colonial cyanobacteria, probably 
biased due to the easy collection and large density of these strains (Gerwick et al. 2008), further 
studies have shown that both free-living unicellular (Synechocystis, Synechococcus) and more 
complex cyanobacterial strains (Nodosilinea, Leptolyngbya, Pseudoanabaena and Romeria) 
have promising activities towards numerous cancer cell lines (Costa et al. 2014).  
Most of the cyanobacterial metabolites are partially composed of amino acids with 
lipopeptide backbones and the unique structural and functional composition is mainly due to 
modification through oxidation, methylation or various halogenations. Metabolites are mainly 
biosynthesized in large multifunctional megaproteins called multimodular nonribosomal 
polypeptide (NRPS) and mixed polyketide enzymatic systems (PKS). Peptide-based natural 
products produced by this machinery have a tremendous chemical diversity, including not only 
the 20 established L-amino acids, but also other non-proteic amino acids, heterocyclic rings, 
sugars and fatty acids. These peptides can have therefore a wide array of biological activities, 
from antibacterial (Gutiérrez et al. 2010), antimalarial (Tripathi et al. 2011) and anti-
inflammatory (Malloy et al. 2011) activities, amongst others.  
The non-ribosomal peptide system produces cyanobacterial compounds through the 
specific condensation of amino acids and target carboxyl groups, without the need for nucleic 
acids. The NPRS peptide synthesis is mediated by peptidyl carrier protein, a protein composed 
of approximately 80 amino acids, that acts as a scaffold, tethering the amino acid building 
blocks and peptidyl intermediates as they are modified and condensed by other domains of the 
NRPS (Lai et al. 2006). The NPRS genes encoding for the catalytic domains that compose the 
multi-module proteins are some of the largest known genes (Finking & Marahiel 2004). The 
other catalytic domains activate amino acids through other protein domains responsible for 
adenylation, thiolation and condensation of active intermediates (Finking & Marahiel 2004). In 
addition to the core domains are the tailoring domains, responsible for diversity in structure and 
function of NRPs, as the epimerase, cyclization, methyltransferase, and oxidation domains 
(Schneider & Marahiel 1998).  Polyketide enzymatic systems produce polyketides, through the 
polymerization of acetyl and propionyl subunits onto a growing carbon chain, a process 
functionally similar to the fatty acid synthesis in the lipid metabolism (John et al. 2008). Both 
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pathways also share similar functional domains, as ketoacyl synthase, acyl transferase, 
ketoacyl reductase, dehydratase, enoyl reductase, acyl carrier protein and thioesterase (John 
et al. 2008), even though the minimal structure of PKS requires only the domains acyl carrier 
protein, ketoacyl synthase and acyl transferase.  
Lyngbya has been collected in various places, from Papua New Guinea to the Bahamas 
and reported to produce numerous natural products belonging to various chemical classes with 
anti-proliferative, anti-cancer properties (Nagarajan et al. 2012). Metabolites as malyngamides 
and its variants reported from L. majuscula showed weak toxicity in in vitro tests, revealing that 
this metabolites could be feed deterrents. A group of complex and unique cyanobacterial 
metabolites named Portoamides isolated from Oscillatoria sp. cultures, showed allelopathic 
activity towards Chlorella vulgaris and also cytotoxicity activity, on H460 lung cancer cells (Leão 
et al. 2010). Portoamides are four compounds, with similar characteristics of families of natural 
compounds previously described as schytrozin A, pahayokolides and tychonamides (Leão et 
al. 2010). 
Other compounds as the novel apratoxins with both peptide and polyketide moieties have 
shown potent anti-tumor activity. Apratoxin A (figure 3), for example, has highly varied chemical 
constituents that include three methylated amino acid moieties, one regular amino acid unit 
(proline), a tri-substituted double bond containing an unsaturated modified cysteine residue, a 
new dihydroxylated fatty acid moiety and 3,7-dihydroxy-2,5,8,8-tetramethylnonanoic acid 
(Luesch et al. 2001). This particular secondary metabolite exhibited significant in vitro 
  
 
Figure 3 – 2D structure of the secondary metabolites Barbamide (on the left) and Apratoxin A (on the right) (from 
chemspider.com). 
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cytotoxicity in tumor cell lines and in vivo studies revealed complete recovery of an early stage 
of adenocarcinoma in mice (Luesch et al. 2006). The mechanism proposed is the ability of this 
metabolite to induce G1 cell cycle arrest in tumor cells (Luesch et al. 2006). 
Dolastatin peptides are another group of promising metabolites.  Dolastatin 10 was first 
isolated from sea hare D. auricularia, from the Indian Ocean (Poncet 1999), but in fact produced 
by the cyanobacteria Symploca hydnoides and Lyngbya majuscule (Niedermeyer & Brönstrup 
2012). Dolastatin 10 was found to have potent anti-neoplastic activity, with an ED50 in the 
picomolar range, inhibiting microtubule assembly through the disruption of the microtubule 
spindle by binding to tubulin (Mitra & Sept 2004). With a simple chemical structure, the total 
synthesis of the compound was described in 1989 (Pettit et al. 1998). MMAE, the synthetic 
derivative is coupled to monoclonal antibodies and used as therapeutics to B/T-cell 
malignancies and acute myeloid leukemia (Pereira et al. 2015).  
Other variants of Dolastatin (Dolastatin 3) inhibit HIV integrase (Mitchell et al., 2000).  
Halogenated compounds are also common, as for the described barbamide (Figure 2), a mixed 
polypeptide-polyketide that contains an unusual trichloromethyl group (Flatt et al. 2006) with 
molluscicidal activity (Orjala & Gerwick 1996).  
Picocyanobacteria, the simplest cyanobacteria, are also able to produce natural 
compounds with biomedical applications. Hierridin B was isolated from Cyanobium sp.( LEGE 
06113) and had selective cytotoxicity towards HT-29 colon adenocarcinoma cells (Leão et al. 
2013). 
 Specific moieties are presumed to be responsible for the activity of certain 
cyanobacterial products, as unique structural changes in amino acids. Many studies are now 
focusing on the analysis of structure-activity relationship, towards the synthesis of an active 
part alone for both medicinal and biology research and aid the screening of potential activities 
of secondary metabolites.   
1.2.2.3. Leads on bioactive compounds from cyanobacteria with anti-obesity activity 
Some strains of cyanobacteria are commercially available for consumption due to their 
beneficial properties to human health as Arthrospira, Nostoc and Aphanizomenon (Pulz & 
Gross 2004). They are composed of bioactive and beneficial components as carotenoids, γ-
linoleic acid, phycocyanin, fibers, and plant sterols (Ku et al. 2013). Arthrospira, previously 
known as Spirulina, is a filamentous cyanobacteria belonging to the class III (Oscillatoriales) 
usually found in high salt-alkaline water bodies. As a traditional food in Central Africa, studies 
proving its beneficial effects on human health has led to its consumption worldwide. The 
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therapeutic effects, that generally comprise the major three species Arthrospira platensis, 
Arthrospira maxima, Arthrospira fusiformis,  include anti-hypercholesterolemia, anti-
hyperglycerolemia, anti-inflammatory, anti-tumour and anti-viral activities; it is also protective 
of cardiovascular diseases, mainly due to its hypolipidemic, anti-oxidant and anti-inflammatory 
activities (as reviewed in Deng & Chow 2010). Many preclinical studies have been performed 
in various animal models that demonstrated the hypolipidemic activity of Spirulina. Spirulina is 
well recognized for its high protein content and its richness in minerals, essential fatty acids 
and carotenoids, as β-carotene, astaxanthin and canthaxanthin (Miranda et al. 1998), 
phycobiliproteins as c-phycocyanin (Patel et al. 2005), phenolics as synapic, chlorogenic and 
caffeic acids, and anti-oxidant vitamins as Vitamin E (Miranda et al. 1998) . 
Studies revealed that supplementation in diet of Arthospira species, significantly 
ameliorated the hyperlipidemic profiles of high fat/high cholesterol diet, high fructose and high 
sucrose diets, and carbon tetrachloride-induced fatty livers in rats and mice, lowering hepatic 
cholesterol and triglyceride levels (Iwata et al. 1990; Gonzalez de Rivera et al. 1993; Torres-
Duran et al. 1999; Jarouliya et al. 2012; Cheong et al. 2010). 
These results were confirmed in human clinical trials, where supplementation with Spirulina 
species resulted in decreases of plasma triglyceride concentrations and of the ratio of high-
density lipoprotein (HDL) and low-density lipoprotein (LDL) in subjects with T2DM (Parikh et al. 
2001). Spirulina also presents a high content of γ-linoleic acid (around 1.3%), which is 
frequently used to treat rheumatoid arthritis, atopic eczema, acute respiratory distress 
syndrome, cancer, and asthma, and to improve plasma lipid profiles, for its anti-inflammatory 
properties (Fan & Chapkin 1998).  Recent studies report that the in vitro and in vivo anti-diabetic 
effect of Spirulina could be from the active component phycocyanin, a phycobiliprotein that 
lowered body weight, serum and liver triglyceride content  and fasting plasma glucose in KK-
Ay mice (KK mice strain with the yellow obese gene Ay ), most likely by enhancement of insulin 
sensitivity (Ou et al. 2013). However, the inherent high polysaccharide content itself has the 
capacity of lowering insulin and glucose blood levels and promote cholesterol elimination in 
feces (de Jesus Raposo et al. 2013).  
The major component of Spirulina, phycocyanin, accounting for 14% of the cyanobacteria’s 
dry weight (Romay et al. 2003), has been reported to be a potent anti-inflammatory  agent, 
which abolished the TNF-α response in Kupffer cells from mouse liver after thyroid 
calorigenesis induction (Remirez et al. 2002) and reduced inflammatory cell infiltration and 
colonic damage in rats with acetic acid induced colitis (Gonzalez et al. 1999). Other studies 
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described phycocyanin as a powerful antioxidant agent with neuroprotective effects, able to 
scavenge reactive oxygen species (Farooq et al. 2014).  
Diet supplementation with Nostoc commune var sphaeroides Kützing (N. commune) also 
showed a hypocholesterolemic effect in mice, reportedly by reducing intestinal cholesterol 
absorption and stimulating fecal sterol excretion (Rasmussen et al. 2009). Its lipid extract was 
also seen to significantly lower the expression of 3-hydroxy-3-methyl-glutaryl-CoA reductase 
(HMG-coA reductase), a key enzyme for cholesterol biosynthesis, and the levels of mature 
forms of sterol-regulatory element-binding protein 1 and 2 (SREBP-1 and SREBP-2), resulting 
in the decrease of expression of genes involved in cholesterol and fatty acid metabolism 
(Rasmussen et al. 2008). Furthermore, another study reported that the lipid extract of N. 
commune is able to decrease proinflammatory gene expression, evaluating the levels of 
proinflammatory mediators as TNF-α, COX-2, IL-1β, IL-6 in RAW 264.7 macrophages in a 
dose-dependent manner (Park et al. 2008). The anti-inflammatory function may be mediated, 
at least in part, by inhibiting the NF-κB pathway to decrease the production of proinflammatory 
mediators (Ku et al. 2013). 
Cyanobacteria could have major bioactive compounds other that the ones so far described 
with effective lipid-profile improving and anti-oxidant properties. Safety assessments of certain 
cyanobacteria strains are now in development, in order to evaluate if dietary supplementation 
of cyanobacteria may be consumed without toxic side-effects (Yang et al. 2011). 
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2. Objectives 
Studies performed earlier at the Blue Biotechnology and Ecotoxicology Group of CIIMAR 
had already established that some cyanobacterial strains are producers of cyanotoxins and 
secondary metabolites (Martins et al. 2005). The possibility that cyanobacteria could produce 
secondary metabolites with relevant bioactivity for the treatment of obesity or obesity-related 
metabolic complications was based on a literature search on bioactive compounds with anti-
obesity properties from cyanobacteria and other organisms, and on profiles of compounds 
found in cyanobacterial strains (Castro et al., submitted; see Appendix II). 
Our objective was to screen six cyanobacterial strains for the potential production of 
secondary metabolites relevant to anti-obesity studies using a bioassay-guided fractionation 
process. The compounds of cyanobacterial strains were extracted and separated into 62 
fractions. Two endpoints were chosen for the analysis of anti-obesity activities: (i) preadipocyte 
proliferation and (ii) adipogenesis in the 3T3-L1 murine cell line.  
 The sulforhodamine B (SRB) and 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyl tetrazolium 
bromide (MTT) assays were used to estimate the proliferative activity of the prepared fractions. 
ELISA BrdU assay was used as a complementary method to confirm the observed proliferative 
bioactivity in selected fractions.  Regarding the adipogenic activity, Oil Red O staining was 
performed after adipocyte differentiation to quantify the intracellular lipid contents, using a 
combination of imaging and photometrical analyses.  
The overall aim of this study was to isolate and identify novel compounds from the selected 
cyanobacterial strains based on bioactivity screening and subsequent fractionations. For this, 
several chromatographic techniques (VLC, flash chromatography, HPLC, SPE) were used to 
isolate compounds and 1H  NMR to characterize each step of fractionation. 
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3. Materials and Methods 
3.1. Cyanobacterial strains and culture 
 
The Blue Biotechnology and Ecotoxicology Group of CIIMAR offers a large collection of 
cyanobacterial strains isolated from water samples and solid materials from the Portuguese 
coast and freshwater ecosystems over the years. Culturing of cyanobacteria strains was 
performed in order to obtain high total biomass. Cyanobacteria were grown in Z8 medium 
(Kotai, 1972). Cultures were maintained at the constant temperature of 25ºC, with a light 
intensity of approximately 30 μmol photons m-2 s-1 and with a light/dark cycle of 14:10h. During 
the exponential phase, cells were harvested by centrifugation (7 min, 4600 rpm, 4 ºC) or 
filtration, frozen at -80 ºC and freeze-dried. The lyophilized biomass was stored until the 
extraction procedure took place. 
3.2. Extraction and bioassay-guided fractionation  
 
The lyophilized biomass from 6 different cyanobacterial strains was used for a simple liquid 
extraction, which yielded each a cyanobacterial crude extract. A mixture of 
dichloromethane:methanol (2:1) was employed to extract the cellular components of the 
biomass. The cyanobacterial biomass was immersed in the mixture for 10 minutes, and then 
put through the cheese cloth and Whatman Nº1 Filter Paper in a Büchner funnel as shown as 
in Figure 1, with the vacuum on. The resulting liquid phase was collected in a round bottom 
(RB) flask. This process was repeated twice. Heating (<40 ºC) of the mixture using a hotplate 
was further performed for about four times in order to maximize the amount of cyanobacterial 
cellular compounds extracted. Following extraction, the liquid phase collected in the RB flask 
was evaporated in a rotary evaporator. The resulting content in the RB flask was re-suspended 
in chloroform, transferred to a pre-weighed glass vial and dried under vacuum. The mass of 
the crude extract was measured in order to calculate the yield of the extraction procedure. 
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Figure 4 - Apparatus assembly for the extraction of the crude extract, from the lyophilized cyanobacterial biomass. 
The crude extracts obtained are then subjected to a normal phase (silica gel 60, 0.0015-
0.040 mm, Merck, KgaA, Damstadt, Germany) vacuum liquid chromatography (NP-VLC). The 
crude extract was resuspended in the initial eluent mixtures and loaded on top of the silica 
column. The paper filter is added after loading the sample in the silica, to disturbing the silica 
bed on the top of the column. Using a gradient of solvents, from 1:9 Ethyl Acetate 
(EtOAc):Hexane to 1:1000 Trifluoroacetic Acid (TFA):Methanol (MeOH), the crude extract was 
separated in fractions of increasing polarity. The chromatography eluent solutions were 
carefully added stepwise, according to Table 1, and 10 solutions were obtained (A-J), collected 
in RB flasks. These fractions were dried in in a rotary evaporator, re-suspended, transferred to 
pre-weighed vial, dried and weighed before the 1H nuclear magnetic resonance (NMR) (400 
MHz, BrukerAvance III) analysis. This was the general procedure for the first fractionation, 
whose fractions were later used in the screening for biological activity.  
 
Table 1 - Gradients used in the vacuum liquid chromatography (VLC). 
Fraction EtOAc (%) Hexane (%) Methanol (%) TFA (%) Volume (mL) 
A 10 90 - - 500 
B 20 80 - - 200-250 
C 40 60 - - 200-250 
D 50 50 - - 200-250 
E 60 40 - - 200-250 
F 80 20 - - 200-250 
G 100 - - - 200-250 
H 75 - 25 - 200-250 
I - - 100 - 500 
J - - 99,9 0,1 200-250 
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Figure 5 - A) Setup of the fractionation during Fraction B obtainment; B) Close-up of the silica gel column used in 
the vacuum liquid chromatography; C) Apparatus assembly for the vacuum liquid chromatography.  
3.2.1. Normal phase vacuum liquid chromatography of E14028 I 
The bioactive fraction E14028 I was subjected again to a normal phase (silica gel 60, 
0.0015-0.040 mm, Merck, KgaA, Damstadt, Germany) vacuum liquid chromatography (Figure 
4C), a method chosen due to the high mass of this fraction (m=1.7516 g), inappropriate for 
more refined methods as column chromatography. Using a gradient of solvents, from 4:6 
EtOAc:Hexane to neat Methanol, seven different fractions were obtained of increased polarity. 
Fraction E14028 I was suspended in ethyl acetate with the help of ultrasounds, and loaded on 
top of the silica column. The mixtures were carefully added stepwise, according to Table 2, and 
7 solutions were obtained (1-7), collected in RB flasks. The fractions were dried in a rotary 
evaporator, re-suspended, transferred to pre-weighed vial, dried and weighed before the 1H 
NMR (400 MHz, BrukerAvance III) analysis. The obtained fractions were subsequently tested 
in the biological assays. 
 
 
 
A 
B 
C 
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Table 2 - Gradients used in the vacuum liquid chromatography (VLC). 
Fraction EtOAc (%) Hexane (%) Methanol (%) Volume (mL) 
E14028 I1 40 60 - 400 
E14028 I2 80 20 - 300 
E14028 I3 100 - - 300 
E14028 I4 90 - 10 300 
E14028 I5 75 - 25 300 
E14028 I6 50 - 50 300 
E14028 I7 0 - 100 400 
 
3.2.2. Flash chromatography of E14028 I7 
After the biological assays, the most polar sub-fraction (E14028 I7) was found to be the 
most active one. We proceeded then to a normal phase 50 cm length silica column (silica gel 
60, 0.040-0,063 mm, Merck) flash chromatography (Figure 6). The length of this column was 
considered appropriate due to the complexity of the sub-fraction, assessed through 1H NMR 
(400 MHz, BrukerAvance III) spectrum analysis. Using a gradient of solvents, from 1:9 
MeOH:EtOAc to 1:1000 TFA:MeOH, 86 samples were collected in 10 mL tubes. The fraction 
E14028 I7 (m=891 mg) was resuspended in the mixture corresponding to the Mixture 1 and 
loaded onto the silica gel column, stabilized with sand (Sigma-Aldrich) on top. The mixtures 
were carefully added stepwise, according to Table 3. Thin layer chromatography (TLC) (silica 
60 F254 (Merck)) was performed to every eluate and visualized under UV light in order to assess 
the efficiency of the chromatography and to extrapolate the composition of each mixture, as 
elucidated in Figure 7.  Some samples in elution tubes were joint due to assumed similar 
composition as elucidated in Table 4. Sub-fractions were established and evaporated in RB 
flasks. These mixtures were dried in a rotary evaporator, resuspended, transferred to pre-
weighed vial, dried and weighed before the 1H NMR (400 MHz, BrukerAvance III) analysis. The 
obtained fractions were later tested in the biological assays. 
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Table 3 - Gradients used in the flash chromatography, for 
E14028I7 rendering. 
Mixture 
EtOAc 
(%) 
Methanol 
(%) 
TFA 
(%) 
Volume 
(mL) 
1 90 10 - 100 
2 85 15 - 200 
3 80 20 - 200 
4 75 25 - 200 
5 70 30 - 150 
6 65 35 - 150 
7 60 40 - 200 
8 55 45 - 50 
9 40 60 - 100 
10 30 70 - 100 
11 - 100 - 200 
12 - 99,9 0,1 100 
 
 
 
Figure 6 - Elucidatory scheme of flash 
chromatography procedure. 
 
Table 4 - Fraction pooling after thin layer 
chromatography for E14028I7. 
Collection 
Tubes 
Fractions 
1-10 1 
11,12 2 
13-17 3 
18-24 4 
25-29 5 
30-33 6 
34-37 7 
38-52 8 
53-63 9 
64-69 10 
70,71 11 
72-81 12 
82-84 13 
85,86 14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 - Elucidatory scheme of thin layer 
chromatography procedure. 
 
3.2.3. Reverse phase solid phase extraction of E14028 I7 8A+9 
Sub-fraction 8 was difficult to solubilize in chloroform and thus was previously separated 
into two distinct phases: a phase solubilized in diethyl ether and another phase solubilized in 
MiliQ water, originating fraction 8A and fraction 8B, respectively. After 1H NMR (400 MHz, 
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BrukerAvance III) analysis, the bioactive fractions E14028 I7 8A and 9 were joint due to 
assumed similar composition. Before processing, sub-fractions were filtered in Whatman No1 
filter paper to remove silica contamination. Reverse phase solid phase extraction (RP-SPE) 
using a 10g C18-E column (Phenomenex, Torrance, CA, USA) was performed to obtain further 
simpler sub-fractions. Using a gradient of solvents, from 1:1 H2O:MeOH to neat Diethyl Ether, 
105 solutions were collected in collection tubes. The fraction E14028 I7 8A+9 was resuspended 
in 1:1 H2O:MeOH and loaded onto the SPE column. The mixtures were carefully added 
stepwise, according to Table 5. TLC (silica 60 F254 (Merck)) was performed to every eluate, 
each one visualized under UV light and with PMA (Phosphomolybdic acid) stain, in order to 
assess the efficiency of the chromatography and to extrapolate the composition of each 
mixture, as elucidated in Figure 7.  Some mixtures were joint due to assumed similar 
composition as elucidated in Table 6. Sub-fractions were collected and evaporated in RB flasks. 
These mixtures were dried in a rotary evaporator, resuspended, transferred to pre-weighed 
vial, dried and weighed before the 1H NMR (400 MHz, BrukerAvance III) analysis. The obtained 
3rd sub-fractions were later tested in the biological assays. 
 
Table 5 - Gradients used in the flash chromatography, for 
E14028 I7 8A+9 rendering. 
 
  
Collection 
Tubes 
H2O 
(%) 
Methanol 
(%) 
Diethyl 
Ether 
(%) 
Volume 
(mL) 
1-6 50 50 - 40 
7-13 40 60 - 40 
14-20 30 70 - 40 
21-24 20 80 - 20 
25-43 10 90 - 80 
44-56 - 100 - 80 
57-62 - 90 20 40 
62-65 - 80 20 30 
66-70 - 70 30 30 
71-82 - 50 50 60 
83-89 - 25 75 30 
90-105 - - 100 65 
Table 6 - Fraction pooling after TLC for E14028 
I7 8A+9. 
 
 
 
Collection  
Tubes 
Fractions 
1-6 A 
7-24 B 
25-28 C 
29-43 D 
44-51 E 
52-65 F 
66-70 G 
71-92 H 
93-105 I 
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3.2.4. Semi-preparative reverse-phase HPLC for E14028 I7 8A+9 E 
After biological assays, fraction E was selected for further purification by semi-preparative 
HPLC.  A 1525 Binary HPLC pump and a UV-Vis detector (Waters, Milford, MA, USA) were 
used in all semi-preparative separations. The separation of process was carried out with a 
Synergi Fusion-RP column (10 µm, 250 x 10 mm, Phenomenex). Optimization of the separation 
procedure was previously assessed, in order to assure maximum possible separation of 
compounds. The conditions used in the separation after optimization are described in Table 7. 
The chromatogram allowed us to collect the compounds, according to the observed peaks, in 
RB flasks from multiple injections and evaporated in the rotary evaporator. Sub-fractions were 
resuspended, transferred to pre-weighed vial, dried and weighed before the 1H NMR (600 MHz, 
BrukerAvance III) analysis. The obtained 4th sub-fractions were later used in the biological 
assays. 
Table 7 -Mobile phase gradient used for the semi-preparative HPLC on sub-fraction E14028 I7 8A+9 E. 
 
 
 
 
 
3.2.5. Semi-preparative reverse-phase HPLC for E14028 I7 8A+9 E7 
For the simplification of the active sub-fraction E14028 I7 8A+9 E7, semi-preparative 
reverse phase HPLC was used.  Optimization of the separation procedure was previously 
assessed, in order to assure maximum possible separation of compounds. The analytical-scale 
HPLC was performed with a Synergi Fusion-RP column (4 µm, 250 x 4.60 mm,, Phenomenex) 
and with an isocratic program of 75% MeCN/25% H2O, using a flow of 0.5 mL/min. The 
chromatogram allowed us to collect the compounds according to the peaks shown, resulting in 
10 new sub-fractions (E14028 I7 8A+9 E7 A-J). Sub-fractions were collected in RB flasks from 
multiple injections and evaporated in the rotary evaporator. Sub-fractions were resuspended 
and transferred to pre-weighed vial, dried and weighed before the 1H NMR (600 MHz, 
BrukerAvance III) analysis. 
 
 
 
Time Flow (mL/min) 
H2O 
(%) 
Methanol (%) 
0-10 2 40 60 
10-20 2 - 100 
20-40 2 - 100 
40-45 2 40 60 
45-60 2 40 60 
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3.2.6. Semi-preparative reverse-phase HPLC for E14028 I7 8A+9 E7J 
For the simplification of the methanol-soluble sub-fraction E14028 I7 8A+9 E7J, semi-
preparative reverse phase HPLC was used.  Optimization of the separation procedure was 
previously assessed. We used an isocratic program of 85% MeOH/15% H2O, using a flow of 
0.5 mL/min. The analytical-scale HPLC was performed with a Synergi Fusion-RP column (4 
µm, 250 x 4.60 mm, Phenomenex). This process resulted in 7 new sub-fractions ((E14028 I7 
8A+9 E7 J 1-7).Preparation of the collected samples was also performed for the biological 
assays. 
3.2.7. Normal phase solid phase extraction of E14031 D 
Normal phase solid phase extraction (NP-SPE) using a 50g Strata™ SI-1 Silica column 
(Phenomenex) was performed to obtain further simpler sub-fractions of the bioactive VLC 
fraction E14031 D. Using a gradient of solvents, from 100% n-Hexane to 100% MeOH, 10 sub-
fractions were collected. The fraction E14031 D was resuspended in 100% n-Hexane and 
loaded onto the SPE column. The mixtures were carefully added stepwise, according to Table 
8. Sub-fractions were dried in a rotary evaporator, resuspended, transferred to pre-weighed 
vial. Sub-fractions were prepared dried and weighed before the 1H NMR (400 MHz, 
BrukerAvance III) analysis and test solutions were prepared for the biological assays. 
.  Table 8 - Gradients used in the SPE of E14031 D. 
 
Sub-fractions n-Hexane (%) EtOAc(%) Methanol (%) Volume (mL) 
 100 - - 200 
1 95 5 - 700 
2-4 90 10 - 500 
5 87.5 12.5 - 400 
6 85 15 - 300 
7 80 20 - 400 
8 75 25 - 300 
9 - 100 - 500 
10 - 50 50 200 
10 - - 100 200 
 
3.3. Cell culture and bioassays 
3T3-L1 mouse embryonic fibroblasts (ATCC® CL-173™) were used in this study, obtained 
from the American Tissue Culture Collection (ATCC) (Manassas, Virginia, EUA). This pre-
adipocyte cell line was selected since it has been proven to be a reliable tool in many obesity 
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studies (MacDougald et al. 1995). Cells were cultured in DMEM Glutamax medium (Dulbecco’s 
modified Eagle Medium DMEM GlutaMAX™) from Life Technologies (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA), supplemented with 10% (v/v) fetal bovine serum (FBS, Gibco-
Invitrogen), 0.1% (v/v) amphotericin B ((Life Technologies)) and 1% (v/v)  of penicillin-
streptomycin (Pen-Strep 100 IU mL-1 and 10 mg mL-1, respectively) (Life Technologies)). Cells 
were maintained in a humidified atmosphere with 5% of CO2, at 37ºC in the incubator 8000 DH 
(Thermo Scientific, Waltham, MA, United States of America). Cells were cultured in cell tissue 
flasks (Orange Scientific, Braine-l’Alleud, Belgium) and in Petri dishes (Orange Scientific) for 
the cell differentiation assay. Every two to three days, cultures were split 1:3 using 1 mL of 
TrypLE™ Express (Life technologies), before they reach confluence (70 to 80%). TrypLE™ 
Express was used briefly (1-2 minutes) to cause cell detachment, removed and added culture 
medium to resuspend cells, with the aid of multiple pipetting. Cell density was calculated using 
Countess™ Automated Cell Counter (Thermo Fisher Scientific) with 10 µL of medium with 
suspended cells and 10 µL of trypan blue. Cell density for seeding was of approximately 3000 
cells cm-2. 
3.3.1. Cell proliferation assays 
3.3.1.1. Sulforhodamine B assay 
The sulforhodamine B (SRB) assay was used to assess the proliferation rate of the pre-
adipocytes of the 3T3-L1 cell line. SRB is a water soluble dye, with the ability to bind to basic 
amino acid of cellular proteins, hence its use as a measurement of cellular protein content. Pre-
adipocytes were seeded in 96-well plates at a concentration of 4 x 104 cells mL-1 and 24 hours 
later, cells were exposed to fractions and sub-fractions derived from cyanobacteria at a 
concentration of 100 and 50 µg mL-1, respectively. At the end of each experiment, after 24 or 
48 hours of exposure, cells were fixed with ice-cold trichloroacetic acid, adding 25 µL to each 
well, at a final concentration of 0.1 mg mL-1 SRB (AnaSpec, Inc., Fremont, California, USA), for 
1 hour at 4 °C in the dark. Cells were washed with distilled water, air-dried and stained for 15 
minutes with 75 µL of 0.4% (wt/vol) SRB dissolved in 1% acetic acid as described in Teixeira 
et al. (2010). Excess SRB was removed and cells were quickly washed with 1% acetic acid 
several times to remove all unbound SRB. After being air-dried, the bound dye was solubilized 
with 150 μl Tris–HCl (10 mmol/l, pH 10.5), and the absorbance was determined at 492 nm with 
reference at 650 nm on a plate reader (Biotek Synergy HT). The absorbance of cells at Day 0 
(before treatment, after 24 hours of seeding) was determined in order to obtain comparable 
ratios of proliferative activities between treated and untreated cells.  
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Equation 1 - Formulas used in the calculation of the values for the SRB assay. 
 
%  𝐶𝑒𝑙𝑙 𝑃𝑟𝑜𝑙𝑖𝑓𝑒𝑟𝑎𝑡𝑖𝑜𝑛𝑠𝑎𝑚𝑝𝑙𝑒 =  𝐴𝑣𝑒𝑟𝑎𝑔𝑒  𝐴𝑏𝑠492−650 𝑠𝑎𝑚𝑝𝑙𝑒 ÷ 𝐴𝑣𝑒𝑟𝑎𝑔𝑒  𝐴𝑏𝑠492−650 𝐷𝑎𝑦 0 × 100  
% 𝑃𝑟𝑜𝑙𝑖𝑓𝑒𝑟𝑎𝑡𝑖𝑜𝑛  𝑟𝑎𝑡𝑒𝑠𝑎𝑚𝑝𝑙𝑒 =  
(𝐴𝑣𝑒𝑟𝑎𝑔𝑒  𝐴𝑏𝑠492−650 𝑠𝑎𝑚𝑝𝑙𝑒 ÷ 𝐴𝑣𝑒𝑟𝑎𝑔𝑒  𝐴𝑏𝑠492−650 𝐷𝑎𝑦 0)
(𝐴𝑣𝑒𝑟𝑎𝑔𝑒  𝐴𝑏𝑠492−650𝑠𝑜𝑙𝑣𝑒𝑛𝑡  𝑐𝑜𝑛𝑡𝑟𝑜𝑙 ÷ 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐴𝑏𝑠492 −650𝐷𝑎𝑦  0)
× 100 
3.3.2.2. BrdU ELISA assay  
Cell proliferation was also assessed using the Cell Proliferation ELISA BrdU kit (Roche 
Applied Science, Mannheim, Germany) as a more sensitive method for proliferative activity 
assessment. The principle of the assay is the detection of incorporated 5-bromo-20-
deoxyuridine (BrdU) during DNA synthesis by a specific antibody coupled to peroxidase. The 
test was performed according the manufacturer’s protocol. Briefly, pre-adipocytes were seeded 
in 96-well plates at a concentration of 3 x 104 cells mL-1 and 24 hours later, cells were exposed 
to fractions and sub-fractions derived from cyanobacteria at a concentration of 100 and 50 µg 
mL-1, respectively. After 24 and 48 hours, cells were incubated with 10 µM BrdU labeling 
solution for two hours. After this, culture medium was removed, cells were fixed and DNA was 
denatured. Cells were incubated with Anti-BrdU-peroxidase solution for 90 min at room 
temperature and antibody conjugates were removed by washing three times with PBS. 
Tetramethyl-benzidine (TMB) substrate was added to each well and absorbance was 
measured during the course of 30 min (with intervals each 5 min) at 370 nm with reference 
wavelength at 492 nm in a spectrophotometer (Biotek Synergy HT, Winooski, Vermont, USA), 
corrected with blank measurements. All tests were run in triplicate and averaged. 
Equation 2 - Formula used in the calculation of the values of each time point for the BrdU assay. 
% 𝑠𝑎𝑚𝑝𝑙𝑒 =  
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐴𝑏𝑠370−492𝑠𝑎𝑚𝑝𝑙𝑒 −  𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐴𝑏𝑠370−492𝑏𝑙𝑎𝑛𝑘
𝐴𝑣𝑒𝑟𝑎𝑔𝑒  𝐴𝑏𝑠370 −492𝑠𝑜𝑙𝑣𝑒 𝑛𝑡  𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝐴𝑣𝑒𝑟𝑎𝑔𝑒  𝐴𝑏𝑠370 −492𝑏𝑙𝑎𝑛𝑘
× 100 
3.3.2. Cell viability assay / metabolic activity of pre-adipocytes 
The cellular viability was evaluated through the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay (MTT bioassay). The reduction of MTT to formazan is 
directly proportional to the mitochondrial activity and consequently used to indicate the viability 
or metabolic activity of the cells. This was found to be a quick and reliable method to evaluate 
the mitochondrial and metabolic activity of many different compounds, widely used in toxicology 
(Carmichael et al., 1987). For this test, pre-adipocytes from the cell line 3T3-L1 were seeded 
in 96-well culture plates at a concentration of 3.3 x 104 cells mL-1. 24 hours later, cells were 
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exposed to fractions and sub-fractions derived from cyanobacteria at a concentration of 100 
and 50 µg mL-1, respectively. At the end of the experiment, after 24 or 48 hours of exposure, 
10 µL of a 5 mg mL-1 MTT solution (final MTT concentration of 0.5 mg/ml) was added to the 
culture medium. Following, cells were washed once with PBS and the purple-colored formazan 
salts were dissolved in 100 µL DMSO. The absorbance was measured in a spectrophotometer 
(Biotek Synergy HT, Winooski, Vermont, USA), at 550 nm. All tests were run in triplicate and 
averaged. 
Equation 3 - Formula used in the calculation of the values for the MTT assay. 
 
% 𝑠𝑎𝑚𝑝𝑙𝑒 =  
𝐴𝑣𝑒𝑟𝑎𝑔𝑒  𝐴𝑏𝑠550 𝑠𝑎𝑚𝑝𝑙𝑒
𝐴𝑣𝑒𝑟𝑎𝑔𝑒  𝐴𝑏𝑠550 𝑠𝑜𝑙𝑣𝑒𝑛𝑡  𝑐𝑜𝑛𝑡𝑟𝑜𝑙
× 100 
3.3.3. Cell differentiation assay (adipogenesis) 
Cells were seeded in 24-well culture plates (Orange Scientific), using the complete culture 
of one Petri dish for each plate, which makes an approximate concentration of 2x104 cells cm-
2.  Mature adipocytes were obtained after exposing 3T3-L1 pre-adipocytes to differentiating 
agents. Preadipocytes were allowed to grow to confluence (about 48h to 72h). Two days after 
reaching full confluence (day 0 of differentiation), cells were exposed to insulin (10 µg mL-1) 
(Sigma-Aldrich, St. Louis, MO, United States of America), IBMX (500 µM) (Sigma-Aldrich), and 
DEX (250nM) (Sigma-Aldrich). The cocktail was removed after three days and cells were 
maintained in DMEM medium containing insulin (10 µg mL-1), the medium was renewed every 
2-3 days. From Day 0, cells were exposed to a concentration of 100 µg mL-1 for fractions and 
50 µg mL-1 for sub-fractions. The medium and fractions or sub-fractions were renewed every 
2-3 days. 
Following exposure, at Day 12, cells were stained with Oil Red O, a fat soluble dye, which 
stains intra-cytoplasmic triglyceride and lipid content (Ramírez-Zacarias et al., 1992). Briefly, 
the culture medium was removed and mature adipocytes were fixed with 500 µL of 4% (w/v) 
formaldehyde for 1 hour at 2-8ºC. Cells were washed with ddH2O, air-dried and stained with 
300 µL of a mixture of Oil Red O working solution (0.3 %) in isopropanol/distilled water (3:2). 
15 minutes later, after at least two rounds of washing in ddH2O, cell imaging was performed 
using an inverted microscope (Olympus, DX71). For photometrical analysis, the intracellular 
lipid content was dissolved in 100% Dimethyl sulfoxide (DMSO). The absorbance was 
measured at 492 nm with 650 nm reference in a microplate reader (Thermo Electron, Thermo 
Fisher Scientific, Waltham, MA, USA). All tests were run in duplicate for fractions and triplicate 
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for sub-fractions and averaged. For sub-fraction, cell counting was also performed in order to 
obtain the ratio of lipid content per cell, using the cell count of one well per treatment.  
Equation 4 - Formula used in the calculation of the values for the Oil Red O assay. 
 
% 𝑠𝑎𝑚𝑝𝑙𝑒 =  
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐴𝑏𝑠492 𝑠𝑎𝑚𝑝𝑙𝑒 − 𝐴𝑣𝑒𝑟𝑎𝑔𝑒  𝐴𝑏𝑠650 𝑠𝑎𝑚𝑝𝑙𝑒
𝐴𝑣𝑒𝑟𝑎𝑔𝑒  𝐴𝑏𝑠492𝑠𝑜𝑙𝑣𝑒𝑛𝑡  𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝐴𝑣𝑒𝑟𝑎𝑔𝑒  𝐴𝑏𝑠650 𝑠𝑜𝑙𝑣𝑒𝑛𝑡  𝑐𝑜𝑛𝑡𝑟𝑜𝑙
× 100 
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4. Results  
4.1. Screening of cyanobacterial strains for bioactivity 
Cyanobacterial strains were grown during several months in a medium-scale format. When 
the appropriate collected and lyophilized biomass was achieved, the crude extract of six 
cyanobacterial strains (Phormidium sp. LEGE06363, Planktothrix planctonica LEGEXX280, 
Synechocystis sp. LEGE07211, Oscillatoria limnetica LEGE00237, Aphanizomenon sp. 
LEGE03283, Limnothrix sp. LEGE07212) was obtained and extraction codes were given to 
each crude extract (Table 9). The crude extracts were submitted to a normal phase vacuum 
liquid chromatography resulting in several fractions (Table 10).  
Table 9 - Data of the extracts obtained of the cultured and collected cyanobacterial strains. 
Cynobacterial strain Extract Number Aq Number Biomass/g Extract/g Yield/% 
Phormidium sp. LEGE06363 E14026 E14026Aq 16.768 1.7445 10.40 
Planktothrix planctonica LEGEXX280 E14028 E14028Aq 20.983 3.0227 16.20 
Synechocystis sp. LEGE07211 E14031 E14031Aq 24.634 4.4792 18.18 
Oscillatoria limnetica LEGE00237 E14032 E14032Aq 13.435 3.5292 26.27 
Aphanizomenon sp. LEGE03283 E14035 E14035Aq 28.712 4.4260 15.42 
Limnothrix sp. LEGE07212 E14067 E14067Aq 17.114  2.2267 13.10 
 
Table 10 - Data of the VLC fractionations and fractions obtained for the extracts produced. 
Extract Number Fractions Extract loaded/g Total mass/mg Yield/% 
E14026 A-K 1,7278 2303.9 100.0 
E14028 A-I 2,9458 2693.7 91.4 
E14031 A-L 4,4792 3644.5 85.0 
E14032 A-J 3,4723 2945.2 84.8 
E14035 A-J 3,7979 3060.2 80.6 
E14067 A-J 1,8326 1016.3 55.5 
 
VLC is a standard method used at our lab and other natural compound discovery-
oriented projects, since it is a quick, simple and inexpensive technique using silica gel and a 
soft vacuum (Targett et al. 1979; Leão et al. 2013; Leão et al. 2010). VLC allows us to separate 
complex mixtures of compounds (particle size of stationary phase between 15 to 60 µm), as 
the extract produced from the simple vacuum filtration of the cyanobacterial biomass, which 
separates the numerous compounds from the cyanobacterial cells. Using a normal phase 
gradient and at least 9 different solvent mixtures, we produce several polarity oriented fractions. 
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Some disadvantages to this method, resulting in lowered method yield, are the uneven packing 
of the silica gel and sample load. A yield of +100% was obtained for the fractionation of E14026 
(Table 10), which is mainly due to the presence of silica contamination, since silica is partially 
soluble in methanol used in the process. The presence of remaining cyanobacterial cells in the 
extract produced from the simple vacuum filtration results in a higher dry mass of the extract. 
Cyanobacterial cells do no cross the silica gel pores and thus a lower yield can be obtained in 
this step, as happened for E14067 (Table 10). Even though VLC performs with an acceptable 
final yield, VLC is still a gross method for compound separation, which can ultimately result in 
a compound or group of compounds to be distributed in neighboring fractions.  
Our biological assays rely on spectrophotometric analysis in the visible spectrum. Even 
though throughout the assay procedure the wells of the well plates are washed with PBS or 
ddH2O several times, with the complete removal of the medium, a scan (300-700 nm; Figure 
7) of the VLC fractions was performed in order to determine possible interference of the 
compounds in the readings. Fractions C, D, E and F had higher absorbance values, with peaks 
at 420 and 675 nm. However, taking into consideration the analyzed wavelenghts of the 
bioassys (MTT, SRB, BrdU), few interference is to be expected, and mostly corrected by the 
measurement of the reference wavelenght. 
 
Figure 8 - Visible spectrum (300-700 nm) scanning of the E14026 fractions (A-K) produced after VLC fractionation 
(100 µg mL-1 in DMSO). 
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4.1.1. Screening for proliferative activity 
 
 
 
 
Figure 9 - Cell proliferation (SRB assay, first and second graph, using cell proliferation rate and cell proliferation rate 
compared to the solvent control, respectively) and activity of mitochondrial enzymes (MTT assay, third graph), in % 
of solvent control, for the E14026 (Phormidium sp. LEGE06363) VLC fractions (A – K) with the concentration of 100 
µg mL-1, after 24 and 48 hours of exposure. Solvent control corresponded to 1% DMSO and positive control to 20% 
DMSO, using 3 replicate wells per treatment and 6 for control, solvent control and positive control . 
In our test designs, the different fractions from every cyanobacterial strain were tested, a 
control (only medium and cells), a solvent control (1% DMSO), since fraction test-solutions are 
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dissolved in DMSO, and a positive control (20% DMSO), where it is expected to be observed 
cell death. 
In Figure 9, proliferation rate is presented for each fraction and, in a different graph, in 
percentage of solvent control. Cell proliferation specific to each fraction gives a better resolution 
(60 to 250%), however, measurements compared to solvent control will be used throughout as 
they present a more legible way to interpret activity.  Fractions E14026 E and E14026 J (Figure 
9) showed proliferative activity both at 24 and 48 hours of exposure. At 48 hours, the differences 
in cell proliferation between solvent control and both fractions (E, J) were more evident with a 
proliferative activity of 119.44 ± 1.56 % and 117.00 ± 1.01 % in the SRB assay. Similar results 
were observed in the MTT assay, with an increase of 140.5 ± 5.93% and 117.0 ± 1.01 % 
compared to the solvent control, respectively. E14026 I showed only higher metabolic activity 
at 48 hours (164.9 ± 18.61), and no effects were seen in the SRB assay.  
 
 
Figure 10 - Cell proliferation (SRB assay, top) and activity of mitochondrial enzymes (MTT assay, bottom), in % of 
solvent control, for the E14028 (Planktothrix planctonica LEGEXX280) VLC fractions (A – I) with the concentration 
of 100 µg mL-1, after 24 and 48 hours of exposure. Solvent control corresponded to 1% DMSO and positive control 
to 20% DMSO, using 3 replicate wells per treatment and 6 for control, solvent control and positive control . 
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As for the fractions of E14028 (Figure 10), A, H and I showed activity. Fraction E14028 A 
only showed activity in the SRB assay, with an increase of 135.37 ± 9.61 % and 133.35 ± 17.27 
% at 24 and 48 hours, respectively, whereas no alterations were observed for the metabolic 
activity (MTT). For fractions H and I, the increases of cell proliferation at 48 hours (140.28 ± 
21.35 and 159.89 ± 21.8%, respectively) were accompanied by increases in the activity of 
mitochondrial enzymes (MTT) with 112.10 ± 13.1 and 153.30 ±1.82 %, compared to the solvent 
control.  
 
 
Figure 11 - Cell proliferation (SRB assay, top) and activity of mitochondrial enzymes (MTT assay, bottom), in % of 
solvent control, for the E14031 (Synechocystis sp. LEGE07211) VLC fractions (A – L) with the concentration of 100 
µg mL-1, after 24 and 48 hours of exposure. Solvent control corresponded to 1% DMSO and positive control to 20% 
DMSO, using 3 replicate wells per treatment and 6 for control, solvent control and positive control.  
Regarding E14031 (Figure 11), most of the fractions showed no activity, with little 
differences in cell proliferation compared to the solvent control. Fractions E14031 A and B 
showed increases in metabolic activity at 24 hours (142.00 ± 18.68 and 121.15 ± 5.59%, 
respectively), a result that was not observed, however, at 48 hours of exposure. Fractions 
E14031 F, G and H showed remarkable activity inhibiting the metabolic activity (MTT) of the 
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pre-adipocytes (23.10 ± 2.96, 22.88 ± 0.56 and 25.52 ± 11.53 %, compared to the solvent 
control). Concomitantly, there was also a decrease in proliferation rate (SRB).  
 
 
Figure 12 - Cell proliferation (SRB assay, top) and activity of mitochondrial enzymes (MTT assay, bottom), in % of 
solvent control, for the E14032 (Oscillatoria limnetica LEGE00237) VLC fractions (A – I) with the concentration of 
100 µg mL-1, after 24 and 48 hours of exposure. Solvent control corresponded to 1% DMSO and positive control to 
20% DMSO, using 3 replicate wells per treatment and 6 for control, solvent control and positive control . 
Regarding E14032 (Figure 12), most of the fractions maintained cell proliferation rate 
compared to the solvent control in the SRB assay. In contrast, most of the fractions induced 
mitochondrial activity on 3T3-L1 cells (MTT) at 48 hours. Fractions E14032 D, E and F showed 
the highest increases of 161.76 ± 8.36, 154.29 ± 1.87 and 179.78 ± 7.01%, respectively. 
Fractions from E14035 (Figure 13) showed a similar profile, of an increased metabolic 
activity at 48 hours in the MTT assay for the exposure of most of the fractions, except for 
E14035 H and I, which showed decreases in metabolic activity (87.03± 8.55 and 80.00 ± 3.78%, 
respectively). However, in the SRB assay, fractions H and I showed pro-proliferative activity 
(118.50 ± 18.43 and 138.12 ± 5.11%, respectively, of the solvent control at 24 hours of 
exposure). Fraction B had one of the highest increases on metabolic activity at 48 hours for 
this extract (134.07 ± 122.75%) and no changes in cell proliferation (105.89 ± 5.95%). 
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Figure 13 - Cell proliferation (SRB assay, top) and activity of mitochondrial enzymes (MTT assay, bottom), in % of 
solvent control, for the E14035 (Aphanizomenon sp. LEGE03283) VLC fractions (A – I) with the concentration of 
100 µg mL-1, after 24 and 48 hours of exposure. Solvent control corresponded to 1% DMSO and pos itive control to 
20% DMSO, using 3 replicate wells per treatment and 6 for control, solvent control and positive control . 
Regarding the E14067 extract  (Figure 14), fractions A, J and H exerted increases in 
mitochondrial activity (MTT) at  24 hours (118.76 ± 10.06,  132.78 ± 7.10, 142.89  ± 9.46) and 
fractions A, J, I and H at 48 hours (145.85 ± 11.75, 132.47 ± 4.01, 164.24  ±11.91, 143.26 ± 
6.36, respectively). In the SRB assay,  fractions C and D showed mild increases in cell 
proliferation (117.60 ± 4.99 and 101.75 ± 13.10 % at 24 hours of exposure and 109.98 ± 3.93 
and 111.08 ± 7.77 % at 48 hours of exposure), while  decreases in mitrochondrial activity (50-
70% compared to the solvent control) at both time points (MTT). Fractions E14067 E and G 
also strongly inhibited metabolic activity, fraction G accompanied by a decrease in cell 
proliferation of  76.38 ± 12.89 %, compared to the solvent control. Fraction F exerted increases 
in the metabolic activity (MTT) at 24 (123.71 ± 6.45 %) and 48 hours (145.45 ± 5.23), but no 
differences where seen in the SRB assay.  
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Figure 14 - Cell proliferation (SRB assay, top) and activity of mitochondrial enzymes (MTT assay, bottom), in % of 
solvent control, for the E14067 (Limnothrix sp. LEGE07212) VLC fractions (A – J) with the concentration of 100 µg 
mL-1, after 24 and 48 hours of exposure. Solvent control corresponded to 1% DMSO and positive control to 20% 
DMSO, using 3 replicate wells per treatment and 6 for control, solvent control and positive control. 
Some fractions were chosen to be tested in a more advanced assay for cell proliferation 
(BrdU ELISA assay), which is based on the specific incorporation of BrdU in the DNA of the 
dividing cell. In order to determine some of the differences between the MTT and the SRB 
assay, we selected fractions that showed activity in both assay or in only one of the assays 
(see Table 11). The specific antibody binding to BrdU was followed by the measurement of 
colour development for 30 minutes for the determination of highest absorbance time point 
(Figure 15). In Figure 16, absorbance values after 30 minutes of reaction were normalized to 
the values of the solvent control, for the 24 and 48 hours of exposure. Differences between 
treatments were move evident after 48 hours (Figure 15 and 16). After 48 hours of exposure, 
fractions E14035 B, E14032 H, E14028 A and E14067 D showed increases in cell proliferation 
(154.50 ± 14.99, 133.91 ± 16.42, 129.05 ± 9.57, 139.73 ± 19.57, 123.58 ± 19.43%, 
respectively), whereas E14067 F exerted anti-proliferative effects (65.54 ± 12.23%). 
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Figure 15 - Measurement of color development from 0 to 30 minutes for cell proliferation assessment through BrdU 
ELISA assay for VLC fractions E14035B, E14032H, E14028A, E14067D and E14067F with the concentration of 100 
µg mL-1, control and solvent control (1% DMSO) with 2 hour BrdU pulse, after 48 hours of exposure, using 3 replicate 
wells per treatment and 6 for control, solvent control and positive control .  
 
Figure 16 - BrdU incorporation percentage compared to the solvent control for VLC fractions E14035B, E14032H, 
E14028A, E14067D and E14067F with the concentration of 100 µg mL -1, control and solvent control (1% DMSO) 
with 2 hour BrdU pulse, after 48 hours of exposure, using 3 replicate wells per treatment and 6 for control, solvent 
control and positive control. 
Taking a closer look at all the information we obtained from the cyanobacterial screening, 
DMSO had different degrees of activities on cell proliferation and metabolic activity through the 
SRB, BrdU and MTT assay (Table 12). On average, 1% DMSO exerted a decrease on cell 
proliferation of – 20% for SRB assay and of - 55% through the BrdU ELISA assay. Regarding 
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the metabolic activity there was, however, an average decrease of – 15% registered through 
the MTT assay. In the positive control, corresponding to 20% DMSO, where cell death is to be 
expected, there was an average decrease of – 40% registered for SRB, whilst BrdU ELISA 
registered a proliferative activity of only 1.30% compared to the control. MTT assay registered 
a decrease of – 74%. 
Table 11 - Summary of the activities obtained in the screening 
for proliferative activity: comparison between SRB, MTT and 
BrdU ELISA assay for selected cyanobacterial fractions. 
 SRB 
assay 
MTT assay BrdU ELISA 
assay 
E14035 B = ↑ ↑↑ 
E14032 H = ↑↑ ↑ 
E14028 A ↑ = ↑ 
E14067 D ↑ ↓ ↑ 
E14067 F ↓ ↑ ↓ 
Table 12 – Average effect of exposure to 
DMSO after 48 hours, in % of control, through 
SRB, MTT and BrdU ELISA assay. 
 
 
SRB 
assay 
MTT 
assay 
BrdU 
assay 
1% DMSO 79.82 86.36 45.92 
20% DMSO 39.28 26.02 1.30 
 
4.1.2. Bioassay-guided fractionation of E14028 I 
From the results of the cyanobacterial screening, fraction E14028 I (m=1751.6 mg) was 
selected as promising candidate for the isolation of the responsible compound(s). Since we 
had still high fraction mass and a complex mixture (typical of this specific fraction and confirmed 
after the analysis the NMR spectra (appendix I), another VLC was performed in order to simplify 
the sample. The sub-fractionation by vacuum liquid chromatography resulted in 7 sub-fractions. 
Pre-adipocytes were exposed to those sub-fractions at a concentration of 50 µg mL-1 with the 
same experimental design as used in the screening bioassays (Figure 17). Fraction E14028 I7 
had the strongest effect on cell proliferation at both 24 (139.55 ± 18.71%) and 48 hours (117.52 
± 5.54%), without compromising the activity of mitochondrial enzymes at the 48 hours of 
exposure, compared to the solvent control. For further characterization of the proliferative 
activity, the BrdU ELISA proliferation assay (Figure 17) was performed. At 24 hours, a decrease 
in cell proliferation were observed compared to the solvent control (83.62 ± 28.69%), while an 
increase at 48 hours (123.58 ± 19.43%).  
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Figure 17 - Cell proliferation (SRB assay, top) and activity of mitochondrial enzymes (MTT assay, bottom), in % of 
solvent control, for the E14028 I sub-factions (1-7) with the concentration of 50 µg mL -1, after 24 and 48 hours of 
exposure. Solvent control corresponded to 1% DMSO and positive control to 20% DMSO, using 3 replicate wells 
per treatment and 6 for control, solvent control and positive control.  
 
 
Figure 18 - BrdU incorporation percentage compared to the solvent control for VLC fraction E14028  I7 with the 
concentration of 50 µg mL-1, control and solvent control (1% DMSO) with 2 hour BrdU pulse, after 48 hours of 
exposure, using 3 replicate wells per treatment and 6 for control, solvent control and positive control . 
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The limited resolution due to the shortness of the column can lead to inefficient separation. 
The main result is that a compound or a group of compounds may be distributed by neighboring 
fractions. The use of a narrower column, and longer in length, as in the flash chromatography, 
increases the column cross section. Sub-fraction E14028 I7 (m=891 mg) was submitted to flash 
chromatography and TLC was done simultaneously as a screening procedure to extrapolate 
the composition of each sample; samples were afterwards pooled according to the R f  values 
(Table 13). TLC is performed with a silica gel plate with a chromophore that absorbs 254 nm 
UV light. Compounds can screen some of the UV light and therefore can be detected. R f  values 
from the TLC were calculated as according to Figure 7 (section 3.2.2.) and represent the 
distance traveled by the solvent mixture front and the compound, which can be unique for each 
compound. Different solvent mixtures were used according to the ability of the solvent mixture 
to be able to separate the different samples (Table 13).  
Table 13 - Fraction pooling for E14028 I7 with the respective Rf values from TLC after observation under UV light 
(254 nm). 
E14028 I7 
Sub-
fraction 
Collection 
Tubes 
Rf Mobile phase 
1 1-10 0.929 20% MeOH (EtOAc) 
2 11,12 0.704 20% MeOH (EtOAc) 
3 13-18 1.000 20% MeOH (EtOAc) 
4 19-25 0.948 20% MeOH (EtOAc) 
5 26-29 0.692 20% MeOH (EtOAc) 
6 30-32 - 30% MeOH (EtOAc) 
7 33-37 0.818; 0.945 30% MeOH (EtOAc) 
8 38-52 0.741 30% MeOH (EtOAc) 
9 53-63 - 30% MeOH (EtOAc) 
10 64-69 0.696 30% MeOH (EtOAc) 
11 70;71 0.963 50% MeOH (EtOAc) 
12 72-81 0.870 60% MeOH (EtOAc) 
13 82-84 0.746 60% MeOH (EtOAc) 
14 85,86 0.746 60% MeOH (EtOAc) 
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Figure 19 - Cell proliferation (SRB assay, top) and activity of mitochondrial enzymes (MTT assay, bottom), in % of 
solvent control, for the E14028 I7 sub-factions (1-14) with the concentration of 50 µg mL-1, after 24 and 48 hours of 
exposure. Solvent control corresponded to 1% DMSO and positive control to 20% DMSO, using 3 replicate wells 
per treatment and 6 for control, solvent control and positive control.  
Some samples had compositions which were not detectable through TLC, e.g. sub-
fractions E14028 I7 6 and 9 (Table 13). Sub-fraction 8 was separated into two distinct phases 
previous to the bioassays, due to the distinctive composition of this fraction after collection. 
Sub-fraction 8A, soluble in ddH2O, and fraction 9 exerted pro-proliferative effects in 3T3-L1 pre-
adipocytes, with a proliferative activity of 136.84 ± 0.88 and 128.77 ± 1.93 % after 48 hours of 
exposure, respectively, being the highest scores obtained for this group of sub-fractions (Figure 
19) . Concordantly, the MTT assay revealed increases in the activity of mitochondrial enzymes 
at 48 hours of 161.01 ± 5.40, 163.21±3.50 and 169.73 ± 8.26 % for sub-fractions E14028 I7 7, 
8 and 9 respectively. 
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After the close analysis of the 1H-NMR spectra for sub-fractions 8A and 9 we hypothesized 
that they had a similar composition (Figure 20). These sub-fractions fractions were joint, 
originating in sub-fraction E14028 I7 8A+9 with a final mass of 238.9 mg (188.4 mg from sub-
fraction E14028 I7 8A and 50.5 mg from sub-fraction E14028 I7 9). NMR, was a crucial method 
throughout our experiments. NMR is used as a screening technique in several research 
projects, for both comparison of spectral data found in literature or between fractions. Nuclear 
magnetic resonance has been a widely used method, extremely important, aiding the bioactivity 
guided fractionation process and structure elucidation of new metabolites (Pellecchia et al. 
2002; Oldoni et al. 2016). Throughout this work, we used 1H NMR to evaluate the separation 
procedure, since different NMR spectra are obtained for each fraction. Once the compounds 
are pure, 1D and 2D NMR can be used to elucidate the structure of the compounds obtained. 
 
 
Figure 20 - 1H-NMR spectra for sub-fractions 9 (top) and 8A (bottom) in CD3OD (recorded at 400 MHz). 
Up until here, silica gel was used in chromatography techniques and contamination of silica 
occurred, visible at the naked eye. Silica is able to dissolve in mobile phases above 10% MeOH, 
causing large quantities of amorphous solid to form in samples. Simple filtration using using 
Whatman Nº1 Filter Paper and ddH2O eliminates silica residues. The following method used to 
fractionate the bioactive the active sub-fraction E14028 I7 8A+9  was a silica-based C18-E solid 
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phase extraction, since we still had a considerable amount of mass for this fraction and a rather 
complex mixture. Final mass of this sub-fraction was 159.5 mg, which was loaded onto SPE 
C18 column. During SPE separation, several samples were collected and TLC (under UV light 
and with PMA satining) was performed in order to evaluate the composition of each sample 
and determine similarity between samples (Table 14). With PMA staining we can identify other 
compounds as phenolics, alkaloids and steroids. Conjugated organic compounds are able to 
reduce PMA to a molybdenum blue that upon heating appear as dark green spots on a light 
green background.Samples that had the same Rf  values after TLC were combined to new sub-
fractions from this process.  
Table 14 - Fraction pooling for E14028 I7 8A+9 with the respective Rf values obtained from TLC after observation 
under UV light (254 nm) and PMA staining for the samples collected in SPE (left) and after sample assembly in 50% 
MeOH (EtOAc) (right). 
 
E14028 I7 8A+9 Rfs 
Sub-
fraction 
Collection 
Tubes  
Rf Mobile phase 
A 1-6 0.0 
100% MeOH 
B 8-14 0.759 
C 26-28 0.781 
D 30-42 0.820; 0.902 
E 43-50 0.776; 0.862 
F 62-66 0.833 
G 68-73 0.667; 0.833 
H 75-86 0.787 
I 86-105 0.820 
 
E14028 I7 8A+9 
Sub-
fraction 
Rf Mobile Phase 
A 0 
50% MeOH 
(EtOAc) 
B 0.789 
C 0.758; 0.842 
D 0.758; 0.842 
E 0.926 
F 0.884; 0.968 
G 0.947 
H 0.915 
I - 
Fractions derived from SPE (Figure 21) were tested again in the proliferation assay with 
3T3-L1 cells, except for sub-fraction E14028 I7 8A+9 I that had insufficient mass to prepare the 
exposure solution of 2.5 mg mL-1. Sub-fraction E14028 I7 8A+9 E seemed to have the highest 
effect on the cell line, with increases of cell proliferation of 118.33 ± 13.11 % at 24 hours and 
133.28 ± 34.05% at 48 hours of exposure, compared to the solvent control. Regarding the 
activity of mitochondrial enzymes, sub-fractions E14028 I7 8A+9 D and E exerted the strongest 
effects, with increases up to  171.19 ± 13.10 and 199.04 ± 4.59 % at 24 hours and 172.75 ± 
10.86 and 221.27 ± 6.70 % at 48 hours, respectively, compared to the solvent control.  
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Figure 21 - Cell proliferation (SRB assay, top) and activity of mitochondrial enzymes (MTT assay bottom), in % of 
solvent control, for the E14028 I7 8A+9 sub-factions (A-H) with the concentration of 25 µg mL -1, after 24 and 48 
hours of exposure. Solvent control corresponded to 1% DMSO and positive control to 20% DMSO, using 3 replicate 
wells per treatment and 6 for control, solvent control and positive control. 
After the biological assays, fraction E14028 I7 8A+9 E (m=43.5 mg) was selected to be 
processed through HPLC UV-Vis. Two wavelengths were selected to follow the chromatogram 
of the sub-fraction: a wavelength of 280 and 264 nm, which are standard wavelengths used 
with a UV-Vis detector, since most of the organic compounds absorb in these wavelengths 
(Bart 2005; Kazakevich & LoBrutto 2006). Run tests were performed in order to determine the 
mixtures of solvents and the time points for sample collection, in order to achieve maximum 
compound separation. For this method, a gradient of solvents was used, from 60% MeOH 
(H2O) to 100% MeOH, then back to the initial mixture. Samples 1 to 4 were collected at 60% 
MeOH (H2O), sample 5 was collected during ramp to 100% MeOH, sample 6 to 9 were collected 
at 100% MeOH and sample 10 was collected during the return to the initial mixture (Figure 22). 
Exposure solutions were prepared from the samples collected from HPLC UV-Vis (1-10) 
and used in the bioassays (Figure 23). As for the SRB assay, sub-fractions E14028 I7 8A+9 E  
6, 7 and 9 showed the highest activities, with increases of protein content of 110.84 ± 7.52, 
0
20
40
60
80
100
120
140
160
180
200
%
 C
e
ll 
P
ro
lif
e
ra
tio
n
E14028 I7 8A+9
%24H
%48H
0
50
100
150
200
250
%
 A
c
tiv
ity
 o
f 
M
ito
c
h
o
n
d
ri
a
l 
E
n
z
y
m
e
s
24H
48H
Ana Mafalda Castro  2015 
47 
 
134.94 ± 20.31 and 106.63 ± 9.03 % after 24 hours of exposure, respectively. Regarding the 
metabolic activity (MTT assay), sub-fractions E14028 I7 8A+9 E 1, 6 and 7 had the strongest 
effects of 132.85 ± 5.72, 156.82 ± 5.72 and 140.93 ± 9.16% for the 48 hours of exposure, 
respectively, compared to the solvent control. Due to the present bioactivity in the neighboring 
sub-fraction E14028 I76 8A+9 6, visible in Figure 23, we can expect that the compound is 
distributed in both samples (E14028 I76 8A+9 6 and 7) and that the chromatogram peak seen 
in Figure 22, may have underlying not apparent peaks.  
 
Figure 22 - Chromatogram of E14028 I7 8A+9 E showing highlighted sub-fractions that were collected. Conditions 
of the injection were 200 µL at a concentration of approximately 43.5 mg mL -1. 
Following these results, sub-fractions E14028 I7 8A+9 E 1, 6, 7 and 9 were also selected 
for the specific analysis by the BrdU ELISA proliferation assay (Figure 24). Sub-fraction E14028 
I7 8A+9 E 1 exerted a negative effect on the proliferation rate, compared to the solvent control, 
whereas sub-fractions E14028 I7 8A+9 E 6, 7 and 9 increased proliferation in 123.05 ± 30.57, 
119.75 ± 13.13 and 116.24 ± 18.49 % at 24 hours compared to the solvent control, respectively. 
Sub-fraction E14028 I7 8A+9 E7 had a similar pattern to the one obtained in the SRB assay, 
with an increase of 119.75 ± 13.13 at the 24 hours of exposure and a lowered rate at 48 hours, 
compared to the solvent control (106.88 ± 16.16 % for the BrdU ELISA assay and 102.11 ± 
4.59 for the SRB assay). 
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Sub-fraction E14028 I7 8A+9 7 was chosen for further fractionation since it is a lowered 
mass to be processed and thus a higher probability of quickly obtaining the bioactive 
compounds.  
 
Figure 23 - Cell proliferation (SRB assay, top) and activity of mitochondrial enzymes (MTT assay, bottom), in % of 
solvent control, for the E14028 I7 8A+9 E sub-factions (1-10) with the concentration of 25 µg mL -1, after 24 and 48 
hours of exposure. Solvent control corresponded to 1% DMSO and positive control to 20% DMSO, using 3 replicate 
wells per treatment and 6 for control, solvent control and positive control . 
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Figure 24 - BrdU incorporation percentage compared to the solvent control for HPLC fractions E14028  I7 8A+9 E 
1,6,7 and 9 with the concentration of 25 µg mL-1, control and solvent control (1% DMSO) with 2 hour BrdU pulse, 
after 48 hours of exposure, using 3 replicate wells per treatment and 6 for control, solvent control and positive 
control.. 
 
Figure 25 - Chromatogram of E14028 I7 8A+9 E7 showing highlighted sub-fractions that were collected. Conditions 
of the injection were 35 µL at a concentration of approximately 3.8 mg mL -1. 
Based on these results, sub-fractions E14028 I7 8A+9 E 6 and 7 were selected as 
candidates for fractionation. We proceeded to fractionate firstly the sub-fraction E14028 I7 
8A+9 E7 (m=3.8 mg) through HPLC UV-Vis. This sub-fraction was solubilized in MeCN and 
loaded in the apparatus. Using and isocratic program of 75% MeCN/25% H2O, fractionation 
resulted in 10 sub-fractions (Figure 25): A to I recovered directly from the HPLC, with the 
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absorbance peaks used to determine different resulting fractions, and sub-fraction E14028 I7 
8A+9 E7 J that was the mass on the sub-fraction not solubilized in MeCN. 
The resulting sub-fractions were tested for bioactivity through SRB and MTT assay (Figure 
26). The SRB assay demonstrated that all these sub- fractions had a negative activity on cell 
proliferation, with values ranging from 60 to 90% compared to the solvent control, except for 
the sub-fraction E14028 I7 8A+9 E7 J that exerted a positive effect on cell proliferation of 124.80 
± 23.46 and 134.32 ± 25.32 % at 24 and 48 hours of exposure, respectively. The activity of 
mitochondrial enzymes for this sub-fraction was also positive, 124.35 ± 12.442 and 126.27 ± 
1.10 % at 24 and 48 hours of exposure.  
 
Figure 26 - Cell proliferation (SRB assay, top) and activity of mitochondrial enzymes (MTT assay, bottom), in % of 
solvent control, for the E14028 I7 8A+9 E7 sub-factions (A-J) with the concentration of 10 µg mL -1, after 24 and 48 
hours of exposure. Solvent control corresponded to 1% DMSO and positive control to 20% DMSO, using 3 replicate 
wells per treatment and 6 for control, solvent control and positive control .  
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Figure 27 - Chromatogram of E14028 I7 8A+9 E7J showing highlighted sub-fractions that were collected. 
Conditions of the injection were 50 µL at a concentration of approximately 2.65 mg mL -1. 
As described before, the same apparatus and procedure was applied to simplify sub-
fraction E14028 I7 8A+9 E7J. With a mass of 2.65 mg, this sub-fraction was solubilized in 
MeOH and loaded in the HPLC UV-Vis, using an isocratic program of 85% MeOH/15% H2O 
(Figure 27). 7 new sub-fractions resulted from this procedure and were further tested in 3T3-
L1 pre-adipocytes. Tests through MTT and SRB assay revealed that at a concentration of 25 
µg mL-1, none seem to exert any effects in cell proliferation through SRB assay (Figure 28), 
with proliferation ratios ranging from 85 to 110%, compared to solvent control. However, for the 
MTT assay, fraction E14028 I7 8A+9 E7 J 1 revealed a higher score for metabolic activity, with 
an increase of 165.13 ± 11.82 % at 48 hours, compared to solvent control. 
BrdU ELISA assay, allowed us to confirm that a bioactive compound or a group of bioactive 
compounds are present in the sub-fractions E14028 I7 8A+9 E6 and 7 (Figure 24). The lowered 
activity could be a result of the high processing of the sample, which suffered 7 fractionings, 
and thus some chemical and structural modifications that may have taken place. 
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Figure 28 - Cell proliferation (SRB assay, top) and activity of mitochondrial enzymes (MTT assay, bottom), in % of 
solvent control, for the E14028 I7 8A+9 E7J sub-factions (1-7) with the concentration of 25 µg mL-1, after 24 and 48 
hours of exposure. Solvent control corresponded to 1% DMSO and positive control to 20% DMSO, using 3 replicate 
wells per treatment and 6 for control, solvent control and positive control . 
4.1.3. Screening for adipogenic activity 
The following bioassay of preadipocyte differentiation into mature adipocytes was 
performed at the Department of Biochemistry of the Faculty of Medicine of the University of 
Porto. Although optimization of differentiation process was carried out at BBE, CIIMAR, we 
were unable to obtain consistent differentiation rates. 
Several tests were conducted for the adipogenesis assay, looking for any significant 
changes in the differentiation process from the cyanobacterial strains, and for two well-known 
antidiabetic drugs, troglitazone and rosiglitazone, and the phenol resveratrol (Figure 29). 
Resveratrol strongly inhibited adipogenesis (51.82 ± 2.43 % of control), as well as the DMSO 
exposure (0.2%), with an approximate decrease of lipid content of 10% in the adipogenesis 
process. As for rosiglitazone and troglitazone, increases of 208.59 ± 24.61 and 220.74 ± 44.89 
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%, respectively, compared to control, were registered. Resveratrol also showed cell 
detachment and cell death during the differentiation process, along with the poorly 
differentiated pre-adipocytes (Figure 37).  
 
Figure 29 - Results for the adipogenesis assay (Oil Red O staining), in % of control in 3T3-L1 cell line using DMSO 
(0.2%), resveratrol (100 µM), rosiglitazone (0.2 µM) and troglitazone (0.2 µM), after exposure from day 0 to day 12 
of the differentiation process , using 2 replicate wells per treatment and 4 for solvent control . 
The most fractions from E14026 (Figure 30) showed inhibiting activity on adipogenesis, 
which was analyzed by Oil Red O staining and spectrometrical quantification. Fraction E14026 
A exerted the strongest inhibitory effect, 62.23 ± 4.79 % compared to the solvent control, 
followed by fraction E14026 H (69.97 ± 2.31%). 
 
Figure 30 - Results for the adipogenesis assay (Oil Red O staining), in % of solvent control, for the E14026 
(Phormidium sp. LEGE06363) VLC fractions (A – I) with the concentration of 20 µg mL -1, after exposure from day 0 
to day 12 of the differentiation process. Solvent control corresponded to 0.2% DMSO and 2 replicate wells per 
treatment and 4 for solvent control were used. 
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The same activity was observed for the fractions of E14028 (Figure 31). Exposure of pre-
adipocytes during adipogenesis to fractions E14028 B, F, H and J caused cell detachment and 
cell death. Therefore these wells were not used for Oil Red O staining and are not shown in 
Figure 31. Previously, during our proliferation screening, fractions E14028 B and D exerted 
detrimental effects in metabolic activity (MTT) and E14028 F in proliferation rate (Figure 10). 
Fraction E14028 D showed the strongest effect of these fractions inhibiting adipogenesis 77.14 
± 5.97%, compared to the solvent control.  
 
Figure 31 - Results for the adipogenesis assay (Oil Red O staining), in % of solvent control, for the E14028 
(Planktothrix planctonica LEGEXX280) VLC fractions (A – I) with the concentration of 20 µg mL -1, after exposure 
from day 0 to day 12 of the differentiation process. Solvent control corresponded to 0.2% DMSO and 2 replicate 
wells per treatment and 4 for solvent control were used. 
Regarding E14031 (Figure 32), most of the fractions had a stimulatory effect on 
adipogenesis. Fractions E14031 D and H exerted the strongest effects: 233.30 ± 22.42 and 
210.2 ± 33.76 % compared to the solvent control. In contrast, fraction E14031 B inhibited 
adipogenesis (77.23 ± 1.82 %) and fractions E14031 C and G caused cell detachment and cell 
death, and are not shown in the graph. Fractions E14031 C and G were previously identified 
as cytotoxic for 3T3-L1, with decreases in proliferation rate (SRB) and metabolic activity (MTT) 
at 24 and 48 hours of exposure, at a concentration of 100 µg mL-1 (Figure 11).  
Regarding E14032 (Figure 33), exposure to fractions E14032 E, F, G resulted in cell 
detachment and cell death. In the proliferation assay (SRB) these fractions did not, however, 
show evident cytotoxic effects (Figure 12). Fractions E14032 A, B, C, D and I reduced 
adipogenesis ranging from 75 to 96%, the lowest activity corresponding to fraction E14032 A 
(75.74 ± 10.47%). Fractions E14032 H and J increased adipogenesis (123.98 ± 6.33 and 
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122.44 ± 6.73 %, respectively). Fractions E14032 A, B, C and D limited cell proliferation, more 
evidently at 48 hours of exposure (Figure 12).  
 
Figure 32 - Results for the adipogenesis assay (Oil Red O staining), in % of solvent control, for the E14031 
(Synechocystis sp. LEGE07211) VLC fractions (A – I) with the concentration of 20 µg mL -1, after exposure from day 
0 to day 12 of the differentiation process. Solvent control corresponded to 0.2% DMSO and 2 replicate wells per 
treatment and 4 for solvent control were used. 
 
Figure 33 - Results for the adipogenesis assay (Oil Red O staining), in % of solvent control, for the E14032 
(Oscillatoria limnetica LEGE00237) VLC fractions (A – J) with the concentration of 20 µg mL -1, after exposure from 
day 0 to day 12 of the differentiation process. Solvent control corresponded to 0.2% DMSO and 2 replicate wells per 
treatment and 4 for solvent control were used.  
Regarding the exposure to E14035 during adipogenesis (Figure 34), only fraction E14035 
H was detrimental to cells, causing cell death. This fraction showed cytotoxicity only through 
the MTT assay, of 65.30 ± 3.93 and 87.03 ± 8.55% at 24 and 48 hours, respectively (Figure 
13). The remaining fractions did not exert strong effects on adipogenesis, the lowest value 
registered for E14035 B (82.58 ± 2.81%) and the highest differentiation score registered for 
0
50
100
150
200
250
300
L
ip
id
 C
o
n
te
n
t
(%
 o
f 
s
o
lv
e
n
t c
o
n
tr
o
l)
E14031
0
20
40
60
80
100
120
140
L
ip
id
 C
o
n
te
n
t
(%
 o
f 
s
o
lv
e
n
t c
o
n
tr
o
l)
E14032
Ana Mafalda Castro  2015 
56 
 
E14035 J (113.28 ± 4.31%). Fraction E14035B also inhibited cell proliferation and decreased 
metabolic activity at 24 hours of exposure (Figure 13).  
 
Figure 34 - Results for the adipogenesis assay (Oil Red O staining), in % of solvent control, for the E14035 
(Aphanizomenon sp. LEGE03283) VLC fractions (A – J) with the concentration of 20 µg mL -1, after exposure from 
day 0 to day 12 of the differentiation process. Solvent control corresponded to 1% DMSO and 2 replicate wells per 
treatment and 4 for solvent control were used. 
 
Figure 35 - Results for the adipogenesis assay (Oil Red O staining), in % of solvent control, for the E14067 
(Limnothrix sp. LEGE07212) VLC fractions (A – J) with the concentration of 20 µg mL -1, after exposure from day 0 
to day 12 of the differentiation process. Solvent control corresponded to 0.2% DMSO and 2 replicate wells per 
treatment and 4 for solvent control were used. 
For E14067 (Figure 35), fractions E14067 C and G caused cell detachment and cell death 
during adipogenesis. These fractions exerted strong effects in metabolic activity (MTT) at 24 
and 48 hours of exposure (Figure 14). Fraction E14067 E also inhibited metabolic activity 
(MTT), however, no detrimental effects were observed on cell proliferation and adipogenesis 
were observed. On the other hand, fraction E14067 F increased metabolic activity (MTT) of 
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pre-adipocytes, but no positive effects were observed on cell proliferation and adipogenesis. 
Fraction E14067 A inhibited adipogenesis (75.51 ± 2.13%), followed by fractions E14067 F and 
J (84.32 ± 3.59 and 88.05 ± 2.88 %, respectively). No pro-adipogenic fractions were identified. 
In order to understand the adipogenic effect of the pro-proliferative fractions produced in 
the screening for proliferative activity on pre-adipocytes (as detailed in section 4.1.1.1.), 
fractions derived from flash chromatography E14028 I7 were also tested for effects on 
adipogenesis (Figure 36). Fraction E14028 I7 7 increased adipogenesis (129.44 ± 0.75 %) and 
fractions E14028 I7 8A and 9 induced slightly adipogenesis (115.96 ± 12.44 and 109.98 ± 9.07, 
respectively).  
 
Figure 36 - Results for the adipogenesis assay (Oil Red O staining), in % of solvent control, for the E14028 I7 sub-
factions (1-11) with the concentration of 10 µg mL-1, after exposure from day 0 to day 12 of the differentiation process. 
Solvent control corresponded to 0.2% DMSO and 2 replicate wells per treatment and 4 for solvent control were 
used. 
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Figure 37 - Mature adipocytes after Oil Red O Staining under the optical microscope (40x). (1) Example of abnormal 
mature adipocyte; (2) Mature adipocytes exposed to 0.2% DMSO; (3) Mature adipocytes obtained after 12 day 
exposure to E14032 H; (4) Mature adipocytes after 12 days exposure to E14028 I7 7; (5) Mature adipocytes obtained 
after exposure to E14031D; (6) Pre-adipocytes after 12 day exposure to resveratrol. 
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4.1.4. . Bioassay-guided fractionation of E14031 D 
 
  
Figure 38 - Mature adipocytes after Oil Red O Staining under the optical microscope after 12 day exposure to 
cyanobacterial sub-fractions E1431 D 7 (1) and 3 (2), at a concentration of 10 µg mL -1 (40x). 
 
Figure 39 - Results for the adipogenesis assay (Oil Red O staining), in % of solvent control, for the E14031 D sub-
factions (1-10) with the concentration of 10 µg mL-1, after exposure from day 0 to day 12 of the differentiation process. 
Solvent control corresponded to 0.2% DMSO and 3 replicate wells per treatment and 4 for solvent control were 
used.  
For the bioactivity test of these sub-fractions, with the Oil Red O staining and the cell count, 
we are able to adjust the relative lipid content with the cell count for each treatment, in contrast 
with the relative lipid content per well, obtained from the relative absorbance (Figure 39). Sub-
fractions E14031 D 7 and 8 revealed the highest score of Oil Red O per cell of 204.80 ± 14.60 
and 300.00 ± 6.15% compared to the solvent control, respectively. However, from previous 
observation we registered Oil Red O irremovable precipitates in the wells treated with E14031 
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D 8 and 9, which with the lower cell number for each treatment accounted for a higher lipid 
content per cell. Imaging, showing the lowered pre-adipocyte differentiation (Figure 38), 
substantiate these observations.  
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5. Discussion 
5.1. Pro-proliferative and pro-adipogenic activity as targets for obesity treatment 
During obesity, adipocyte hypertrophy and hyperplasia are predominant phenotypes in the 
adipose tissue. In addition, impaired adipocyte differentiation, enlarged adipose cells, hypoxia, 
inflammation and fibrosis are related to a dysfunctional adipose tissue. This is a major driving 
force promoting metabolic disease and the diabetes epidemic (Gustafson et al. 2009; Sun et 
al. 2011). When adipose tissue stops accommodating excess calorie intake due to expansion 
or differentiation impairment, lipodystrophy can take place. In this scenario, adipose tissue 
displays degenerative conditions (macrophage infiltration, cell death, insulin resistance). 
Excess fat is also detrimental since it may start to accumulate in other tissues as the liver 
leading to e.g. steatosis, non-alcoholic fatty liver disease (Danforth 2000). The control of 
adipose tissue processes has a central role in metabolic regulation: recent understandings of 
strategies for obesity therapeutics indicate that adipocyte hypertrophy and dysfunction could 
be avoided if preadipocyte recruitment is enabled (Sethi & Vidal-Puig 2007). In fact, anti-
diabetic drugs as thiazolidinediones (rosiglitazone, troglitazone and pioglitazone) are currently 
in the market, used to restore insulin sensitivity and glucose tolerance, which are described as 
some of the metabolic complications of obesity. These drugs act as PPARγ agonists, which is 
beneficial to the enhancement of adipogenesis and glucose uptake. Thus, an important 
endpoint to reduce the metabolic complications of obesity is the maintenance of the ability to 
recruit adipocytes and to undergo differentiation in order to distribute  the excess calorie intake 
(energy) among competent adipocytes (Tchoukalova et al. 2008; Gustafson et al. 2013; 
Henninger et al. 2014). In this context, the stimulation of adipocyte proliferation and 
differentiation could be beneficial to accommodate the surplus energy and to reduce the obesity 
associated co-morbidities as diabetes, fatty liver disease or cardiac disease. Following this 
strategy for the treatment of obesity associated co-morbidities, we aimed to identify novel 
compounds that could be used to diminish the metabolic complications of obesity. 
Regardless of this above described strategy, the inhibition of adipocyte differentiation has 
been extensively studied and several studies have described that inhibition of adipogenesis 
can be beneficial and simultaneously ameliorate obesity symptoms when using a whole animal 
model system. Target herbal ingredient, extract made from two herbs, Scutellariae Radix and 
Platycodi Radix, caused the downregulation of adipogenic transcription factors in 3T3-L1 
mature adipocytes, as well as adipogenesis (through Oil Red O staining) and triglyceride 
content. In the animal model, target herbal ingredient caused a reduction of body weight and 
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total serum cholesterol, and improved the glucose tolerance in high-fat diet induced obese 
mice, after a daily dose administration for 10 weeks (Han et al. 2011). The ethanol extract of 
Laminaria japonica (Areshoung) also decreased lipid droplets, adipocyte size and body weight 
gain in Sprague-Dawley male rats (Jang & Choung 2013). Licochalcone A and 18β-
glycyrrhetinic acid from licorice, in two distinct studies, decreased body weight and plasma 
triglycerides in obese animal models and reduced lipid accumulation and key adipogenic genes 
and receptors (as PPAR-γ, C/EBPα, SREBP-1)  in 3T3-L1 adipocytes (Quan et al. 2012; Park 
et al. 2014). Other compounds, as the antioxidant tanshinone IIA from Salvia miltiorrhiza also 
suppressed adipogenesis through PPARγ antagonism in 3T3-L1 adipocytes, but reduced 
adipose tissue mass and body weight and improved glucose tolerance in high fat diet induced 
obese mice (Gong et al. 2009). This shows that different endpoints (both the inhibition and 
promotion of adipogenesis) are useful in the study of obesity treatments, since decreases in 
adipogenesis do translate in lowered body weight gain in the whole animal model system.  
However, this approach needs careful analysis of the mechanistic profile and of potential 
side effects of the studied compounds. 18β-glycyrrhetinic acid is thought to reduce 
adipogenesis and lipogenesis via cannabinoid receptor type 1 inactivation. Drugs that act as 
antagonists of this receptor have been known to have serious repercussions in the central 
nervous system as anxiety and depression, even though they are recognized to effectively 
lower body weight (Nathan et al. 2011). Many other drugs developed for the treatment of 
obesity have severe side-effects; diethylpropion increased blood pressure and heart rate; 
thyroxine leads to hyperthyroidism, anxiety and insomnia; sibutramine, a norepinephrine and 
serotonin reuptake inhibitor caused headache, insomnia and constipation; phenylpropanol 
amine, a central α1-adrenergic receptor agonist caused hemorrhagic stroke and psychosis. 
These drugs have been withdrawn and banned in most countries (reviewed in Cheung et al. 
2013; Kim et al. 2014). Thus, the history of pharmacotherapy for obesity treatment shows that 
solely inhibiting weight gain may not be a viable solution due to the many secondary effects.  
An appropriate methodology to different obesity scenarios should be met in order to treat 
its complications. In our work, the focus was to identify cyanobacterial secondary metabolites 
that could treat and prevent metabolic complications of obesity as insulin resistance and 
adipocyte hypertrophy. In this context, our research focused on the pro-proliferative and pro-
adipogenic bioactivity of compounds. 
Ana Mafalda Castro  2015 
63 
 
5.2. Cyanobacterial assessment for bioactivity 
Many studies have pointed to the benefits of cyanobacteria for human health. Some strains 
of cyanobacteria effectively ameliorate the hyperlipidemic profile in animal and human models 
(Iwata et al. 1990; Gonzalez de Rivera et al. 1993; Torres-Duran et al. 1999; Jarouliya et al. 
2012; Cheong et al. 2010), or have shown protective properties against inflammatory diseases, 
cancer, diabetes and hypercholesterolemia (Parikh et al. 2001). Cyanobacterial secondary 
metabolites are mostly lipopeptides (40%), amino acids (5.6%), fatty acids (4.2%), macrolides 
(4.2%) and amides (9%). The chemical identity of compounds from cyanobacteria with the 
highest pharmaceutical and biotechnological interest tends to be lipopeptides (Raja et al. 
2015). Cyanobacteria have shown to be prolific in secondary metabolites, with up to 800 
described in literature; examples include antioxidant vitamins, phenolic compounds, sterols or 
polyunsaturated fatty acids. Their array of bioactivity is very wide and, at the same time, they 
have shown to have specific interactions with cellular targets, which represent a major 
advantage for pharmaceutical, medicinal and biotechnological fields. Compounds isolated from 
cyanobacteria have been shown to induce G1 cell cycle arrest in tumor cells (Luesch et al. 
2006), inhibit microtubule assembly (Mitra & Sept 2004), inhibit HIV integrase (Mitchell et al., 
2000) and can be selectively cytotoxic to a cell line (Leão et al. 2013). As highlighted before 
(Section 1.2.2.3.), cyanobacteria hold as well many beneficial effects to treat obesity and 
related co-morbidities. Species of Arthospira present anti-hypercholesterolemia, anti-
hyperglycemia, anti-inflammatory and anti-oxidant activities in the human and animal model. 
N. commune has also been described to reduce obesity complications in vivo. Research is now 
focusing on describing the bioactive compounds responsible for these valuable activities.  
Some studies indicate that phycocyanin, a phycobiliprotein with anti-oxidant activity 
(Farooq et al. 2014), found in many strains of cyanobacteria  (Liu et al. 2014), could act as an 
anti-diabetic drug (Ou et al. 2013). Phycocyanin significantly decreased the body weight, 
fasting plasma glucose, serum triglyceride content and enhanced glucose tolerance in KKAy 
mice (Ou et al. 2013). Scytonemin is a yellow-brown hydrophobic pigment from cyanobacteria 
that acts as a protection for UV-A radiation. Scytonemin has anti-inflammatory and anti-
proliferative activities (Stevenson et al. 2002) and is produced by many cyanobacterial species 
(Rastogi et al. 2013). γ-Linoleic acid is another cyanobacterial compound under intense study. 
This rare polyunsaturated fatty acid is 170-fold more effective than linoleic acid and can 
represent up to 1% of the dry cell mass (Cohen et al. 1993). This compound was isolated in 
1967, is easily converted in arachidonic acid and prostaglanding E2 in the human body, which 
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lowers blood pressure and plays an important role in the lipid metabolism (Euler & Eliassen 
1967).  
In our work, we tested 62 fractions from six freshwater cyanobacterial strains of three 
different sub-classes (Oscillatoriales, Chrococcales, Nostocales) for proliferative and 
adipogenic activity. Summarizing, many of those fractions were able to exert effects in the 3T3-
L1 cell line. In total, we observed four different activities: inhibiting or inducing the proliferation 
or differentiation of the (pre-) adipocytes.  
Our present results confirm the ability of cyanobacteria to interact with many cellular 
targets. Fractions of Planktothrix planctonica LEGEXX280 (E14028 I) and Aphanizomenon sp. 
LEGE03283 (E14035 B) exerted strong positive effects in proliferative and metabolic activity of 
3T3-L1 pre-adipocytes. Fractions from Synechocystis sp. LEGE07211 (E14031 D) and from 
Oscillatoria limnetica LEGE00237 (E14032 H and J) showed remarkable activity in the 
modulation of adipogenesis of murine pre-adipocytes.  
Furthermore, even though we focused on the pro-proliferative and pro-adipogenic activity 
as strategy for the treatment of obesity-associated co-morbidities (as outlined above), our 
results show promising bioactivities that can be relevant for other areas of drug discovery (anti-
proliferative, anti-adipogenic). Fractions from Phormidium sp. LEGE06353 (E14026 A) and 
Synechocystis sp. LEGE07211 (E14031 B) strongly inhibited adipogenesis in 3T3-L1 cells. 
Since adipogenesis and osteoblastogenesis are tightly connected (Pittenger 1999), each 
lineage being exclusively induced, many studies have explored the potential of bioactive 
fractions inhibiting adipogenesis for their effects on the promotion of osteoblastogenesis (Byun 
et al. 2012; Karadeniz et al. 2014; Kim et al. 2015).  
Fractions from Phormidium sp. LEGE06353 (E14026 H), Synechocystis sp. LEGE07211 
(E14031 F and G) effectively decreased cell proliferation.  Inhibition of cell proliferation is often 
used as a method for the screening of new anti-cancer compounds (mainly through anti-
proliferative, pro-apoptotic signaling) and to study the etiology of cancer (Shoemaker 2006; Yu 
et al. 2014; Rubinstein et al. 1990). It has been an endpoint studied in hepatocellular carcinoma 
(Gedaly et al. 2013), breast cancer (Spink et al. 2006) and several cancer cell lines (Song et 
al. 2006; Leão et al. 2013; Costa et al. 2014; Catchpole et al. 2015).  
5.2.1. E14028 I pro-proliferative activity 
From the extract of Planktothrix planctonica LEGE XX280, we obtained 9 fractions, E14028 
I being the active one. Our bioassay guided activity fractionation of E14028 I yielded up to 44 
sub-fractions after 7 fractionation processes: 2 VLCs, a flash chromatography, a SPE and 3 
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HPLCs. Throughout, several sub-fractions were found to be bioactive; the most promising ones 
were selected to follow bioactivity. As a result, E14028 I7 8A+9 E7 J1 comprises the bioactive 
compound responsible for the pro-proliferative activity in 3T3-L1 cells. Hereby, the compound 
was isolated from Planktothrix planctonica, which is a freshwater species. This genus includes 
filamentous planktonic cyanobacteria that grow through a solitary trichome (filament) without 
sheaths, and since they present no akinets or heterocysts, they are grouped in the sub-class 
Oscillatoriales (Komárek & Jaroslava 2004). Some strains of this genus are known to produce 
cyanotoxins as microcystins (Ernst et al. 2001) and other peptides with up to 15 different 
chemotypes (out of 18 different peptides) (Welker et al. 2004). However, there is no novel 
secondary metabolite described yet with biotechnological potential from this species or genus 
of cyanobacteria.  
Until now, we can elaborate that this is a polar compound, a secondary metabolite from the 
cyanobacteria Planktothrix planctonica LEGE XX280 that increases both cell proliferation and 
metabolic activity of 3T3-L1 pre-adipocytes, with a relative high absorbance at 254 and 280 
nm, soluble in methanol and water.  This compound is now isolated with few impurities in its 
composition. Due to the lack of purified mass of the isolated compound, we are not able to 
proceed towards mass spectrometry and compound identification (through e.g. MarinLit, a 
database of marine natural products). Since this compound may be distributed in another 
fraction (E14028 I7 8A+9 E6) we will proceed to isolate the compound from this fraction in order 
to obtain appropriate mass for further identification and characterization.  
Compounds like these, acting on the increase of cell proliferation, can contribute to 
ameliorate the metabolic complications of obesity, since pre-adipocyte proliferation is a key 
component of adipose tissue development. In other disease areas, a pro-proliferative 
compound can also be of interest.  Cellular proliferation is an important endpoint for therapeutic 
areas as for  neurodegenerative disorders (Popa-Wagner et al. 2015) and fibroblastic wound 
healing (Werner et al. 2007; Styrczewska et al. 2015; Geller et al. 2015). Specifically in the area 
of wound healing, where cell proliferation and tissue regeneration is limited, the application of 
pro-proliferative compounds has been studied. Glycolic acid, a hydroxyacetic acid commonly 
found in some sugar crops, is a compound used in several cosmetic products to ameliorate 
photoaging processes and enhance wound healing. In in vivo and in vitro experiments, 
treatment with glycolic acid increased collagen mRNA expression and dermal fibroblast 
proliferation (Kim et al. 1998). In cultured human skin fibroblasts, treatment with glycolic acid 
resulted in increased cell proliferation and collagen production in a dose-dependent manner 
(Kim & Won 1998). Studies described that flax fiber hydrophobic extract activated migration 
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and proliferation of NHDF and NHEK cells (Styrczewska et al. 2015). It is known that this extract 
contains cannabidiol, phytosterols and unsaturated fatty acids, however, no single compound 
was described to be responsible for the bioactivity. The ethanolic extract of the leaves of 
Hancornia speciose Gomes, a medicinal plant from Brazil used to treat wounds and 
inflammation, revealed in vitro wound healing properties. The extract increased cell migration 
and proliferation of fibroblasts, as well as anti-inflammatory properties. The isolated 
compounds, bornesitol and quinic acid, were also bioactive (Geller et al. 2015). Thus, 
cyanobacteria may hold a promising source of pro-proliferative compounds in other disease 
contexts. 
In the context of obesity, proliferative activity has been used as an endpoint in several 
obesity-related studies (Teixeira et al. 2010b; Marques et al. 2013). In previous studies, natural 
products inhibiting adipogenesis also decreased pre-adipocyte proliferation. Treatment of 3T3-
L1 pre-adipocytes and human pre-adipocytes with curcumin inhibited mitotic clonal expansion 
and further resulted in the inhibition of mRNA levels of adipogenic transcription factors as 
PPARγ and C/EBPα in the early stage of adipocyte differentiation (Kim et al. 2011). The extract 
of Populus balsamifera L. led  to a complete inhibition of adipogenesis and severely limited 
3T3-L1 proliferation (Martineau et al. 2010). Treatment of 3T3-L1 cells with xanthohumol, a 
prenylflavonoid from Humulus lupulus L., also decreased differentiation, lipid content and 
PPARγ expression and the proliferation of pre-adipocytes measured through SRB staining 
(Mendes et al. 2008). On the other hand, the extracts of the inner bark of Alnus incana ssp. 
rugosa, acting as a partial agonist towards PPARγ, did not affect clonal expansion of pre-
adipocytes (Martineau et al. 2010). Hence, studies confirm an intrinsic relation between 
proliferation and adipogenesis, the two major endpoints controlling the metabolic complications 
of obesity. Once there is available mass to conduct an adipogenesis study, new information 
will be obtained on the effects of this compound exerted during adipogenesis. The increase of 
pre-adipocyte proliferation exerted by the compound present in E14028 I7 8A+9 E7 J1 could 
all by itself contribute to ameliorate adipocyte hypertrophy and dysfunction as more competent 
adipocytes may be available to accommodate surplus energy.  
5.2.2. Cyanobacterial adipogenic bioactivity 
Oil Red O staining was used for the assessment of the effects of the cyanobacterial  
fractions during adipogenesis, a fat soluble dye. ORO is accepted as the most accurate method 
for the diagnosis of steatosis in mouse and human liver (Catta-Preta et al. 2011; Levene et al. 
2012) and has been widely used in 3T3-L1 adipocytes (Kim et al. 2009; Marques et al. 2013; 
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Ko et al. 2013; Jung et al. 2014). ORO is a low budget method and requires basic laboratory 
apparatus. The principle is simple: the dye is minimally soluble in solvent and, when in contact 
with the cells or tissue, the hydrophobic dye will quickly associate with the lipids. Oil Red O 
stains hydrophobic and neutral lipids, as triglycerides, diacylglycerols and cholesterol esters, 
whereas most polar lipids, as phospholipids, sphingolipids and ceramides, are not stained by 
the dye (Fowler & Greenspan 1985).  
Imaging is a crucial tool to understand phenotypic variations of adipocytes when exposed 
to fractions or compounds. A high Oil Red O score means higher lipid content per well and the 
lipid content may be distributed in many and small adipocytes or in few and large adipocytes. 
The latter case is an undesirable result, since this correlates with a hypertrophic phenotype and 
dysfunctional adipose tissue due to lack of adipogenesis committed cells. Moreover, even 
though each well is seeded with the same cell density, the cell number per well may vary from 
the beginning of the treatment until the end of the experiment. In Figure  37 (1), we captured 
an abnormal adipocyte, high in size and lipid content, in contrast with a lack of differentiation in 
the rest of the well. This result was obtained during optimization of the differentiation process. 
In Figure 37 (2), the effect of 0.2% DMSO is shown on adipogenesis. Some differentiation takes 
place and clear lipid droplets are formed, however, not in every treated cell. In contrast, 
fractions E14031 D (Figure 37 (5)) and E14032 H (Figure 37 (3)) showed increased 
adipogenesis that resulted in higher scores of Oil Red O and in the desired phenotypic changes 
of mature adipocytes with more than 80% of differentiated cells after the 12 day treatment. 
Imaging allowed us to conclude that E14031D exerted stronger effects, with a higher number 
of differentiated cells after 12 days and a uniform lipid accumulation, without the formation of 
hypertrophic adipocytes. 
Fractions E14031 D (Synechocystis sp. LEGE07211) and E14032 H (Oscillatoria limnetica 
LEGE00237) exerted the most substantial effects on adipogenesis. These are derived from two 
strains of distinct classes of cyanobacteria, Synechocystis sp. LEGE07211 belongs to the sub-
class Chroccocales and Oscillatoria limnetica LEGE00237 to the sub-class Oscillatoriales. 
Researchers have pointed to more complex bacteria (from sub-class Oscillatoriales, 
Nostocales or Stigonematales) as more prolific in secondary metabolites. However, our 
bioassays show that simpler cyanobacteria can also possess novel secondary metabolites with 
pharmaceutical and biotechnological potential. This is in agreement with a previous work done 
at our laboratory (Costa et al. 2014). Synechocystis sp. is a unicellular picoplanktonic 
cyanobacterial genus. Strains of this genus have been identified to have a high carotenoid 
content (mainly β-carotene and zeaxanthin) and thus could present anti-oxidant properties. 
Ana Mafalda Castro  2015 
68 
 
Several fatty acids and volatile compounds with antimicrobial activity, and pigments were 
already isolated from this genus (Plaza et al. 2010). However, no bioactive anti-obesity 
compounds were identified yet.  
The bioactive fraction was chosen for further fractionation through SPE and resulted in 10 
new fractions (E14031D 1-10). In order to overcome the existing differences in cell number per 
well, an extra well was added that was used for cell counting after trypsinization in the end of 
the experiment. Cell number registered for each treatment varied between 1.9 and 8.5 x 105 
cells/well. In comparison, the addition of the cell count showed a more pronounced effect of the 
sub-fraction E14031 D 7, the most active sub-fraction of the group (Figure 38). From imaging, 
E14031 D 7 also exerted an apparent evenly differentiation of the pre-adipocytes (Figure 39 
(1)).  
Sub-fraction E14031 D 7 was eluted in 20% EtOAc (n-Hexane) and has a blue color in this 
solution. Analysis of the 1H NMR spectra indicated us this is a fairly simple sub-fraction and 
thus HPLC separation will be performed. Phycocyanin is a known blue pigment with anti-
diabetic properties and could be suspected to be present in our cyanobacterial extracts. Most 
of the described optimized techniques for phycocyanin isolation are, briefly, aqueous extraction 
and precipitation of the protein in ammonium sulfate followed by centrifugation, 
ultracentrifugation or filtration (Furuki et al. 2003; Gantar et al. 2012; Kumar et al. 2014; 
Chethana et al. 2015). The aqueous extract we prepared in our work should contain the protein 
extract of the cyanobacterial strains. However, we assume that phycocyanin was not 
solubilized in our organic solvent mixture dichloromethane:methanol (2:1) and is not present in 
this fraction. Further tests will be necessary to characterize the composition of our active 
E14031 D7 sub-fraction. 
In our in vitro tests, we assayed the activity of resveratrol, a phenol known for its biological 
and pharmacological properties, and two thiazolidinediones: troglitazone and rosiglitazone. 
Resveratrol caused a decrease on adipogenesis of 51.82 ± 2.43 % compared to the control 
(Figure 37 (6)), as well as cell death and detachment after the 12 day exposure at a 
concentration of 100 µM. This is in agreement with the literature, which described an inhibition 
of adipogenesis (Zhang et al. 2012; Santos et al. 2014) and apoptosis on doses above 10 µM 
of resveratrol in differentiating cells (Hu et al. 2014; S. Chen et al. 2015). Hu et al. (2014) 
described, however, that under physiologically achievable doses (1 and 10 µM) adipogenesis 
is enhanced, as well as increases of the glucocorticoid receptor and PPARγ, possibly 
synergistic.  Resveratrol exposure in 3T3-L1 pre-adipocytes, however, did not affect cell 
viability at concentrations up to 1.8 mM (Zhang et al. 2012).  
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The same pattern was obtained for several cyanobacterial fractions, as for E14026 A 
(Figure 30) and E14067 A (Figure 35) that inhibited cell differentiation. Cell death and cell 
detachment were observed in response to the exposure to fractions E14035 H, E14028 B, F, 
H and J, and E14032 E, F and G at a concentration of 20 µg mL-1. 
 Thiazolidinediones are recognized as beneficial molecules for the treatment of T2DM 
(Oakes et al., 1994, Young et al., 1995, Petersen et al., 2000, Smith et al., 2000), acting as 
agonists of PPARγ. PPARγ controls many cellular events as adipocyte differentiation and lipid, 
carbohydrate and amino acid metabolism. Thiazolidinediones are heterocyclic organic 
compounds that share a thiozolidine, a saturated ring with a thioeter and an amine group in the 
1 and 3 positions, respectively (Schoonjans & Auwerx 2000). They are able to reverse the 
insulin resistance by restoring insulin-induced translocation of the glucose transporter GLUT4 
towards the cell membrane in adipocytes. This results in a lowered blood glucose levels, 
beneficial to T2DM patients (Anil Kumar & Marita 2000; Martinez et al. 2010; Karimfar et al. 
2015). 3T3-L1 pre-adipocytes treated with troglitazone also showed enhancements on the rate 
of differentiation of adipocytes, by increasing the expression of the adipocyte-specific 
transcription factor, C/EBPα, as well as increased uptake of glucose (Tafuri 1996). In addition, 
these molecules seem to have anti-inflammatory activity, since NF-κB levels were decreased 
after administration of rosiglitazone in patients (Pan et al. 2014; Chen et al. 2015). Our results 
were in agreement with the literature, balanced increases of adipocyte differentiation and lipid 
accumulation occurred when cells were treated for 12 days with 0.2 µM of troglitazone and 
rosiglitazone.  
During our cyanobacterial screening, many fractions could act as potential PPARγ 
agonists, as remarkable increases in adipogenesis were observed after a 12 day exposure to 
20 µg mL-1. Once a cyanobacterial compound is isolated and characterized, future studies will 
focus on the mechanistic pathway through which these compounds are able to exert their 
effects. Previous studies have used this approach on natural product discovery: PUFAs from 
fish oil (Flachs & Hal 2005), dysidine, a sesquiterpene quinone from the Hainan sponge 
Dysidea villosa (Zhang et al. 2009), two plastoquinones, sargaquinoic acid and 
sargahydroquinoic acid, from Sargassum yezoense (Kim et al. 2008) and the extract of Alnus 
incana (Martineau et al. 2010) acted as agonists for PPARγ and led to increased adipogenesis. 
Although most research on natural compound discovery focuses on the inhibition of weight gain 
and adipogenesis, this approach is beneficial for the enhancement of glucose tolerance, for the 
prevention of fat accumulation in non-fat depots, and to ameliorate metabolic complications. 
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The combination of both activities, the pro-proliferative and pro-adipogenic effect on 3T3-
L1, is also beneficial since the recruitment of pre-adipocytes and the presence of competent 
adipocytes are equally important, as discussed before. During our bioactivity guided 
fractionation for pro-proliferative effects on 3T3-L1 adipocytes, 11 fractions resulting from the 
flash chromatography (E14028 I7 1-11) were tested in pre-adipocytes in order to evaluate their 
effects in adipogenesis (Figure 36). Our fractions or interest, E14028 I7 7, 8A and 9, showed 
increases in adipogenesis compared to the solvent control. The highest score was obtained for 
E14028I7 7 (Figure 37 (4)). The bioactive fractions E14031D and E14032 H increased the 
adipogenesis and no changes were registered in the proliferation rate, compared to the solvent 
control. These are promising activities in this context. The approach on drug discovery can 
focus on peripheral or central targets, although a combined approach can lead to more efficient 
strategies (Dietrich & Horvath 2012). A combination therapy, with one compound increasing 
pre-adipocyte proliferation and another compound increasing adipogenesis, could be a 
valuable tool for the disease. However, since these two endpoints are tightly connected, 
different natural cyanobacterial compounds can be obtained from this research work, with 
different mechanism of action.  
5.3. Methodology for the analysis of cell proliferation 
Two tests were performed routinely for the screening assay on cell proliferation, one 
measuring protein content that correlates with cell proliferation (SRB assay) and another one 
used for measuring the metabolic activity (MTT assay). Sulforhodamine B is a red dye used for 
protein stain. This amino heterocyclic dye binds to basic amino-acid residues, under low pH 
conditions. The use of tris-HCl (pH 10.5) results in the dissociation of the dye and suitable 
spectrophotometric analysis (Vichai & Kirtikara 2006). This method has been used for  
cytotoxicity assays and cell proliferation assessment (Teixeira et al. 2010b; Faria et al. 2010). 
The MTT assay requires cellular metabolic activity to reduce the tetrazole ring of MTT into 
purple formazan crystals. Conversion of the tetrazolium ring to the formazan crystals is mainly 
performed by mitochondrial succinic dehydrogenases, the crystals accumulating in endosomal 
and/or lysosomal compartments, being later transported out of the cell by exocytosis (Liu et al. 
1997).  
The used of these two assays is beneficial and helps avoiding technical misinterpretation. 
Some compounds that affect pH can directly interfere with MTT-formazan absorption (λmax), 
without compromising cell viability, or with the cell density itself (Plumb et al. 1989), which does 
not happen for SRB assay. The MTT assay is  classically used for cell viability but can also be 
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a measure of cell proliferation and metabolic activity (Sieuwerts et al. 1995; Grenho et al. 2015; 
Lee et al. 2015), although it may overestimate the number of viable cells, when compared to 
other methods as trypan blue determinations (Wang et al. 2010).  Previous studies indicated 
that SRB assay has a smaller variability on cell enumeration than the MTT assay(van Tonder 
et al. 2015) and has been described to provide a better linearity with cell number (Keepers et 
al. 1991) which are major advantages for scientific research and medicine. Due to its high 
reproducibility, at the present, the SRB assay is preferred by the National Cancer Institute in 
the USA as a high-throughput assay, used widely for compound screening (Shoemaker 2006).  
Nonetheless, MTT assay is still considered as a golden standard, an assay similarly suitable 
for high-throughput screening (Hamid et al. 2004) and important in this context of metabolic 
research.  
To understand the effects of cyanobacterial fractions in the 3T3-L1 pre-adipocytes we 
further compared selected results obtained by MTT and SRB to the BrdU ELISA assay. BrdU 
ELISA is a frequently used semi-quantitative method applied to measure cell proliferation, as 
an alternative to the radioactive nucleoside 3H-thymidine labelling in newly synthesized DNA. 
The colorimetric assay based on the anti-BrdU-POD reaction is suitable for routine screening 
for studies that need to elaborate on cell proliferation mechanisms and regulation. BrdU is the 
non-radioactive chemical analog of 3H-thymidine. This assay involves the incorporation of BrdU 
into newly synthesized DNA, a DNA denaturation step and immobilization with an anti-BrdU 
antibody and quantification of incorporated BrdU through a peroxidase-conjugated anti-BrdU 
antibody (Magaud et al. 1988; Muir et al. 1990). This technique is a rapid and sensitive 
quantification of DNA synthesis through a colorimetric detection, suitable for experiments in cell 
lines, and in vivo and ex vivo experiments (Behl et al. 2006). For our fast growing cells, a 2 
hour exposure for the BrdU incorporation was found to be necessary to establish the minimum 
interval for the maintenance of the linearity of the results – between 0.5 to 1.5 absorbance units. 
BrdU ELISA assay confirmed that the selected cyanobacterial fractions are commonly 
beneficial for cell fitness and proliferation (Figure 16). A similar pattern to the one obtained for 
the regular tests with MTT and SRB assays is also observed, in which most of the pro-
proliferative effects are more evident at 48 hours of exposure. 
Comparing these three assays (Table 11), both SRB and MTT assay are important to the 
study of proliferation of pre-adipocytes. The most active fractions on proliferation through BrdU 
ELISA assay (E14035 B and E14032 H) had a concomitant increased activity through MTT 
assay, where an increase of metabolic activity is observed. However, for fractions E14067 D 
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and E14067 F, BrdU ELISA was in agreement with the results obtained through the SRB assay, 
but not with the MTT assay (Table 11).  
 Looking at the average effect of exposure of the pre-adipocytes to DMSO (Table12), 
the MTT underestimated the inhibitory activity of 1% DMSO exposure in cell metabolism, a 
phenomenon already described for this assay (Wang et al. 2010). However, for the 20% DMSO 
exposure, where cell death is expected, the MTT assay was more sensitive and presented 
closer values to the ones obtained with the BrdU ELISA assay. This can be explained since 
SRB does not distinguish dead cells from live cells, whereas MTT only detects viable cells. 
Summarizing, BrdU is a more sensitive assay but comparatively more expensive as it uses 
an ELISA detection. This makes it not suitable for the medium scale screening of cyanobacterial 
compounds, but aids in the confirmation of results. Bioactivity may be detected either through 
MTT or SRB assays, although BrdU was seen to be generally in accordance with the SRB 
assay. The use of both methods seem to be a cost-effective methodology to screen bioactive 
compounds with proliferative activity.  
5.4. Bioactivity-guided fractionation for compound discovery 
Bioactivity guided-fractionation is a classic method for novel natural compound discovery 
that relies on extract preparation, fractionation, biological screening with relevant assays and 
the isolation, purification and structural elucidation of the active compounds. This process has 
been very helpful for the discovery of compounds for specific targets, usually with the aid of 
chromatographic techniques as liquid chromatography, HPLC, liquid-liquid or solid phase 
extraction (Oldoni et al. 2016). Bioactivity guided fractionation can be time consuming and 
expensive, since high volumes of solvents are used. Moreover, this process can often result in 
the elucidation of a compound already described in literature and has the limitation of 
occurrence of synergisms and antagonisms between compounds that can ultimately result in 
the loss of activity or the blocking of the activity of a compound, respectively. Another 
disadvantage is that this method is resource consuming. After each step of fractionation,  
preparation of exposure solutions is needed, which results in losses of biomass of the sub-
fractions. In case of bioassay failure or need for concentration readjustment, extra mass for 
solution preparation is required. However, this approach ensures that a compound with a 
specific biological activity is identified. This is the case of the discovery of hexapeptides with 
anti-fouling activity (Sera et al. 2003), proanthocyanidins with anti-oxidant activity (Oldoni et al. 
2016), α-glucosidase Inhibitors from Vauquelinia corymbosa (Flores-Bocanegra et al. 2015), 
lignans from the root of Machilus obovatifolia (Lin et al. 2015), among others. 
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Other approaches allow the identification of novel secondary metabolites. Some research 
is based upon the identification of new compounds and the consequent purification from a 
mother mixture without the previous knowledge about bioactivity. Isolated compounds with 
chemical identities of interest are further screened for specific bioactivities, a process that 
contrasts with the classic bioactivity guided-fractionation. This has resulted in the isolation of 
several natural products of interest from varied organisms as xanthones from Garcinia 
succifolia (Duangsrisai et al. 2014), sansalvamide, a cyclic depsipeptide from a marine fungus 
of the genus Fusarium (Belofsky et al. 1999). 
Dereplication techniques is often used in novel natural compound discovery to discriminate 
previously characterized compounds in an early stage of the research, before pursuing the 
process of isolation and characterization. This process is based on analyzing the spectroscopic 
features at the level of the crude extract and following the compounds with non-characterized 
features, increasing the potential to elucidate and identify novel secondary metabolites. The 
most common uses of dereplication are UV spectroscopy and mass spectrometry combined 
with HPLC (LC-UV/PDA, LC-MS) that allow the identification of certain structural classes and 
gives leads on the molecular weight and formula (Hubert et al. 2014).  
Another recent approach is the on-line coupling of biochemical detection assays with 
HPLC. As reviewed in Malherbe et al. (2012), enzyme activity/affinity detection and receptor 
affinity detection are some types of biochemical detection that have been developed for the 
detection of acetylcholinesterase inhibitors, α-glucosidase inhibitors, liver cytochrome P450 
ligands, HIV-protease inhibitors, estrogen receptor ligands, among others. This technique uses 
a conventional HPLC as a first step and then the mobile phase gets separated into two distinct 
branches: one to the biochemical detector and another one for substance detection (e.g. UV 
detector) and identification (e.g. ESI-TOF-MS). Some limitations to these processes can be the 
lack of sensitivity for bioactivity testing, the bioactivity can be too complex to be automated 
(poor availability or stability of biocomponents and targets) and, as this is a complex setup, 
there is a need for an extensive and expensive method development.  
Intricate and complex models can be used in mass identification of novel compounds. 
However, they often lack in flexibility and a previous method development is needed, which is 
time consuming. In this perspective, a bioactivity guided fractionation is a more versatile 
technique. In our lab, this approach allows to find novel secondary metabolites with a bigger 
range of bioactivities and to explore the cyanobacterial biotechnological and pharmaceutical 
potential. 
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6. Conclusion 
The present work aimed to identify novel cyanobacterial secondary metabolites that could 
be useful for the treatment of the metabolic complications of obesity. 60 fractions derived from 
six cyanobacterial strains were screened for activity on preadipocyte proliferation, metabolic 
activity and adipogenesis.  
The results showed that the selected fractions of cyanobacteria possess activities that can 
aid in the treatment of obesity and two distinct groups of compounds are to be isolated. Sub-
fractions of Planktothrix planctonica LEGEXX280 (E14028 I), from Oscillatoriales, and 
Aphanizomenon sp. LEGE03283 (E14035 B), from Nostocales, exerted strong effects in 
proliferative and metabolic activity of 3T3-L1 pre-adipocytes. A sub-fraction from Synechocystis 
sp. LEGE07211 (E14031 D), a more simple cyanobacteria belonging to the Chroccocales 
genus, also showed interesting activity in the modulation of adipogenesis of murine pre-
adipocytes. These results confirm that unicellular free-living species of cyanobacteria are 
prolific in secondary metabolites with bioactivity of interest. 
The polar bioactive compound present in E14028 I7 8A+9 E7 J1 is now isolated and ready 
for chemical identification and structure elucidation with the aid of mass spectrometry and NMR 
spectroscopy, respectively. Sub-fraction E14031 D7 is being processed through HPLC, and 
further isolation of the bioactive compound will follow. We expect to obtain at least two bioactive 
secondary metabolites from this work. Once the pure bioactive compounds are obtained and 
fully characterized, our future work will focus on the mode of action of these compounds using 
molecular biological tools. 
These compounds may be significant tools to treat the metabolic complications of obesity, 
through the increase pre-adipocytes available in the adipose tissue and through the increase 
of differentiated and competent adipocytes to accommodate surplus energy. Further tests on 
adipocytes and other adipose tissue related cell lines will allow us to characterize the effects of 
the compound(s) on obesity-related co-morbidities in more details. 
To the best of our knowledge, this is the first work focusing on bioactivity guided isolation  
of novel cyanobacterial secondary metabolites for the treatment of obesity and obesity related 
co-morbidities.  
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8. Appendixes  
 
Appendix I – 1H NMR data for sub-fractions resulting from E14028I successive fractionings. 
 
 
Figure 1 – 1H NMR spectral data for E14028I in CD3OD (recorded at 400 MHz). 
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Figure 2 – 1H NMR spectral data for E14028 I7 in CDCl3 (recorded at 400 MHz). 
 
Figure 3 – 1H NMR spectral data for E14028I7 8A in CD3OD (recorded at 400 MHz). 
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Figure 4 – 1H NMR spectral data for E14028I7 9 in CD3OD (recorded at 400 MHz). 
 
 
Figure 5 – 1H NMR spectral data for E14028I7 8A+9 E in CD3OD (recorded at 400 MHz). 
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Figure 6 – 1H NMR spectral data for E14028I7 8A+9 E6 in CD3OD (recorded at 400 MHz). 
 
 
Figure 7 – 1H NMR spectral data for E14028I7 8A+9 E7 in CD3OD (recorded at 400 MHz). 
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Figure 8 – 1H NMR spectral data for E14028I7 8A+9 E7 J1 in CD3OD (recorded at 600 MHz). 
 
 
Figure 9 – 1H NMR spectral data for E14031D in CDCl3 (recorded at 400 MHz). 
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Figure 10 – 1H NMR spectral data for E14031D7 in CDCl3 (recorded at 400 MHz). 
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Appendix II - Abstract for the review paper “Obesity: the metabolic disease, advances on drug 
discovery and natural product research”  
 
Castro, M., Preto, M., Vasconcelos, V. and Urbatzka, R. (submitted) “Obesity: the metabolic 
disease, advances on drug discovery and natural product research”, Current Topics in 
Medicinal Chemistry.  
 
Abstract: Obesity is a global health threat. OECD reported that more than half (52%) of the 
adult population in the European Union is overweight or obese. Obesity and obesity -related 
co-morbidities have deep negative effects on morbidity, mortality, professional and personal 
quality of life. Health-care costs represent a negative impact of this disease, with an associated 
economic cost of 100 billion US$ per year in the United States. The most prescribed drugs for 
obesity treatment worldwide are Orlistat, and Phentermine/Topiramate extended release, while 
the major prescribed drug for the same disease in the US are Exenatide and Dapaglifozin. The 
so far developed drugs, targeting weight loss, have a long history of malignant secondary 
effects. There is still a lack of efficient and safe drugs to treat obesity and related metabolic 
complications since in many cases cure cannot be reached by bariatric surgery or healthy 
lifestyle habits. Terrestrial and aquatic organisms are a promising source of valuable, bioactive 
compounds, often with low risks for human health. Some of the natural compounds or 
organisms have been used for centuries by humans as traditional medicine foods. In this 
review, we give insights into the adipose tissue function and development, and the progress in 
traditional anti-obesity pharmacotherapy. A major focus is to highlight the state of the art of 
natural compounds with anti-obesity properties and their potential as candidates for drug 
development; an overview is given about natural compounds derived from different marine 
animal sources, cyanobacteria, marine phytoplankton, fungi or plants. 
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Appendix III – Oral communication "In vitro screening assay using the murine pre-adipocyte 
cell line 3T3-L1 to study anti-obesogenic activities of chemical compounds" at the IJUP - 
Encontro de Investigação Jovem da Universidade do Porto, 13-15th of May, 2015, Oporto, 
Portugal. 
Abstract: Obesity is a global health threat with several etiologies. Standard obesity treatment 
may not be enough to treat obese people that represent more than half of the European Union 
population. The 3T3-L1 cell line has been widely used for the study of bioactive natural 
compounds research, including research of anti-obesity properties of several natural 
compounds as phloratannins from the brown algae Ecklonia stolonifera or meridianins from the 
tunicate Aplidium meridianum. Cyanobacteria, known as blue-green algae and producer of 
cyanotoxins, have shown high content in secondary metabolites with relevant activity. We are 
currently exploring the chemical richness of these prokaryotes by testing cyanobacterial strains 
regarding their anti-obesogenic activity in (pre)adipocyte cells. Various cyanobacterial strains 
were grown and their extracts were produced through simple vacuum filtration of their liofilized 
mass suspended in a mixture of Dichloromethane and Methanol (2:1).  These extracts were 
then fractioned using vacuum liquid chromatography. Bioactivity of the fractions was tested in 
the proliferation assay of preadipocyte cells. Proliferation can be assessed by the 
Sulforhodamine B (SRB) staining and the incorporation of Bromodeoxyuridine (BrdU) into the 
DNA.  Furthermore, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay 
(MTT bioassay) delivers information about the cellular viability and metabolic activity, through 
the reduction of MTT to formazan by mitochondrial activity.  
The most polar fraction (eluded with 100% MeOH) of the cyanobacterial strain 
Planktothrix planctonica has shown the strongest effect on cell proliferation (above 50% 
compared with the solvent control). The same was verified for the MTT assay, where the activity 
of mitochondrial enzymes was increased. After consequent sub-fractionation, purified fractions 
were obtained and the most polar fraction (fraction 7) showed once again pro-proliferative 
activity through SRB and MTT assay. Further column chromatography will allow us to purify 
the single compound responsible for this activity and enable us to elucidate its chemical 
structure. 
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Appendix IV - Poster communication "In vitro screening assay using the murine pre-adipocyte 
cell line 3T3-L1 to study anti-obesogenic activities of chemical compounds" at the ICAAE - 
International Conference on Alternatives to Animal Experimentation, 8 and 9th of May, 2015, 
Lisbon, Portugal (Appendix II). 
 
